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ABSTRACT 
Karen Elizabeth Swietek: The Patient-Centered Medical Home: Impact on Racial/Ethnic 
Disparities in Quality of Care 
(Under the direction of Marisa Domino) 
 
Objective: The objective of this research is to investigate the effects of the patient-
centered medical home (PCMH) model on disparities in quality of care among populations 
with major depressive disorder (MDD) and comorbid chronic physical conditions. 
Methods: Applying instrumental variable techniques to account for differential 
selection into treatment, we used generalized estimating equations and generalized linear 
models to determine the probability of receiving eight disease-specific quality measures for 
adults age 18-64 years with MDD and diabetes. Our independent variables of interest were 
enrollment in a National Committee for Quality Assurance (NCQA) recognized patient-
centered medical home (PCMH), as well as level of NCQA recognition. We used a rank-and-
replace method to measure disparities between racial groups, based on the Institute of 
Medicine definition. 
Results: We found that while PCMH enrollment may improve overall quality of care, 
the effect is inconsistent across racial groups and not always associated with reductions in 
racial/ethnic disparities in quality. We found no association between level of NCQA PCMH 
recognition and improvement in quality. Finally, we found that considerable HTE exists 
among PCMH enrollees, and this heterogeneity is driven by patient race, sex, age, rurality, 
and number of chronic comorbidities. 
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Conclusions: Our findings suggest that the PCMH model alone may be insufficient to 
meet the needs of diverse patient populations. Providers and policymakers should consider 
racial/ethnic disparities and heterogeneous treatment effects explicitly when designing, 
implementing, and evaluating PCMH programs. 
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CHAPTER 1: INTRODUCTION 
Overview 
Persons with multiple chronic conditions utilize health care services more frequently 
and access a wider range of services than the general population,1,2 making coordination of 
their care more difficult. Because mental health problems also exacerbate the disability 
associated with physical disorders and complicate their management,3 these coordination 
challenges make persons with co-occurring mental illnesses such as less likely to receive 
recommended services.1,4 Additionally, racial minorities with psychiatric comorbidities may 
be particularly vulnerable to low-quality care. 
The patient-centered medical home (PCMH) model is an increasingly popular 
intervention to improve quality of care for this complex population. Several provisions of the 
Affordable Care Act (ACA) incentivize the use of accredited PCMH models for patients with 
comorbid mental and physical health conditions.6 But while the rationale for PCMH 
transformation is well-documented,7,8 different patient populations may not benefit equally 
from this model, and the effect of PCMH on racial disparities in quality of care is unknown.9 
The overall objective of this study is to investigate the effects of the PCMH model on 
racial disparities in quality among populations with comorbid depression and chronic 
physical conditions. The central hypotheses are that the PCMH model will improve overall 
quality of care and reduce racial/ethnic disparities, and that practices that achieve higher 
NCQA recognition levels will see greater reductions in disparities. This objective is analyzed 
through three specific aims: 
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Aim 1: Estimate the effect of PCMH enrollment on racial/ethnic disparities in 
quality of care for adults with depression and one or more other chronic medical 
conditions. 
Hypothesis 1.1: PCMHs will provide higher rates of guideline-concordant care 
compared to other models of primary care. 
Hypothesis 1.2: PCMHs will see greater reductions in racial/ethnic disparities in 
quality of care compared to other models of primary care. 
This retrospective cohort study will control for differential selection into the PCMH 
using county rates of PCMH adoption as an instrumental variable (IV). 
Aim 2: Determine whether disparities in quality of care for patients with depression 
and other chronic conditions vary with level of NCQA recognition (level 1, 2, or 3). 
Hypothesis 2.1: PCMHs with higher levels of NCQA accreditation will provide 
higher rates of guideline-concordant care overall 
Hypothesis 2.2: PCMHs with higher levels of NCQA accreditation will see greater 
reductions in racial/ethnic disparities compared to lower recognition levels. 
This study will analyze the same mental and physical health quality indicators as aim 
1 to assess variations in quality of care for Medicaid-enrolled adults receiving care from 
providers with different levels of NCQA PCMH recognition. 
Aim 3: Identify the subgroups of adults with depression and other chronic 
conditions most likely to benefit from PCMH participation. 
Hypothesis 3: PCMH enrollment will have heterogeneous effects on quality; 
individualized treatment outcomes will vary by race, age, gender, rurality, and number of 
comorbidities. 
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This analysis will use a person-centered treatment (PeT) effects model to understand 
heterogeneity of individual-level treatment effects among diverse subpopulations of PCMH 
enrollees by examining the intersection of patient characteristics including age, gender, 
rurality, and number of comorbidities. Using county rates of PCMH adoption as an IV, this 
model will identify the marginal distributions of individual treatment effects based on 
different combinations of individual characteristics. 
These studies have important policy implications and will contribute to a more 
detailed understanding of how the PCMH model affects quality of care for diverse 
populations. Specifically, these analyses will produce empirical evidence on the potential of 
the PCMH model to reduce racial/ethnic disparities in quality of care, determine whether 
level of NCQA recognition plays a role in the receipt of quality care, and provide insight into 
which subpopulations benefit the most from PCMH enrollment. 
Significance 
The relationship between race, depression, and chronic disease outcomes is 
complex,5,10 and concurrent mental and chronic physical illness is an area in which outcomes 
are known to be poor.2 Moreover, racial/ethnic disparities have been well-documented 
among persons with chronic disease and mental illness;11 a higher proportion of individuals 
in minority communities have unmet mental and physical health needs.11,12 Although 
minorities experience mental illness at approximately the same rate as the white population, 
minority patients are less likely to receive timely and appropriate treatment. The factors 
driving disparities in quality of care are not completely understood, but cost of care, social 
stigma, and the fragmented organization of services have been identified as barriers that may 
disproportionately prevent racial minorities with mental illnesses from accessing quality 
care.11 
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Given that minorities are more likely to seek mental health services in primary care 
than from a mental health specialist,12 understanding the potential for primary care models to 
address the intersection between race, depression, and chronic disease is critical to reduce 
health disparities in this population.5,10,13 The PCMH is a model of primary care 
transformation that aims to improve outcomes, safety, system efficiency, and patient and 
provider experiences by offering enhanced care coordination and disease management.7,14,15 
Multiple organizations certify PCMH status, but the most widely used recognition program 
was developed by the National Committee on Quality Assurance (NCQA) in 2008.16 The 
NCQA offers three possible recognition levels, based on the number of PCMH elements 
adopted by a practice.6 Practices can obtain the required number of points for each 
recognition level from a flexible set of criteria, although there are certain “must-pass” 
elements required of all practices.17 
A growing body of literature demonstrates that this model is effective and that PCMH 
transformation is associated with improved clinical outcomes and patient experience of care.6 
Research also suggests that the populations that can most benefit from this model are those 
that require long-term management of their conditions such as chronic disease and behavioral 
health patients.18 However, empirical evidence about the effects of this model on racial 
disparities in quality of care is limited. 
Because the PCMH is being widely adopted, assessing the potential of the PCMH 
model to reduce disparities has significant policy implications. Several provisions of the 
ACA encourage PCMH models for populations with multiple chronic conditions and 
behavioral health needs, including enhanced federal funds for states implementing a variant 
of the model in their Medicaid programs.6 Thanks in part to these incentives, adoption of the 
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PCMH model is growing quickly; between 2009 and 2013 the number of PCMH initiatives 
in the U.S. increased from 26 to 114.19,20 By 2012, half of all states had implemented 
payment reforms encouraging expansion of the PCMH model for their Medicaid 
populations.20 However, racial/ethnic disparities are not well-documented or widely 
evaluated in PCMH initiatives.7,9 Despite the limited evidence, policymakers and providers 
largely believe that the PCMH has the potential to reduce racial disparities.9 
Innovation 
This project addresses a significant gap in the literature by generating new knowledge 
about the impact of the PCMH model on the delivery of equitable, high-quality care. This 
topic is understudied; only a limited number of empirical studies have examined the effect of 
the PCMH on disparities in healthcare and results have been mixed.21–25 This study adds to 
the knowledge base by generating an empirical analysis of the association between the 
PCMH model and disparities in receipt of quality care.  
This project is innovative in two important ways. First, this research leverages a novel 
dataset, leading to substantial increases in the knowledge base on the PCMH model and 
racial disparities in quality. This work constructs a unique dataset by combining five sources 
of data: 1) Medicaid claims from three states (North Carolina, Georgia, Texas); 2) NCQA 
PCMH recognition data; 3) physician and practice-level data from the National Plan and 
Provider Enumeration System (NPPES) Downloadable File; 4) county-level socioeconomic 
status (SES) data from the U.S. Census Bureau’s Small Area Income and Poverty Estimates; 
and 5) county-level mental health provider supply variables from the Area Health Resource 
File. Both the NCQA recognition data and the NPPES file are only recently available for 
research. This is an innovative and relevant contribution to the field because many existing 
PCMH initiatives utilize incentive structures that base payments on NCQA recognition 
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level,26 yet research examining the association between of NCQA recognition level and 
quality outcomes is limited. 
Second, this study assesses heterogeneity of treatment outcomes related to PCMH 
enrollment using a person-centered treatment (PeT) effects model. This is a relatively new 
statistical method is based on local instrumental variable (LIV) techniques.27,28 While IV 
methods are frequently used in the health economics literature to address selection bias, less 
attention has been paid to the appropriate use of IV methods if treatment effects are 
heterogeneous.28 The PeT approach assesses individual-level heterogeneity in an 
observational data setting by taking individual treatment choices into account to predict 
individualized treatment effects.27 Using LIV methods, PeT models can explore treatment 
effect heterogeneity across both observable characteristics and unobserved confounders.27 
The PeT model is particularly relevant to disparities research, because documentation of 
health inequalities is often done with a focus on a single category of difference (e.g. 
race/ethnicity, sex, rurality).29 Analyses such as this one have the potential to improve 
population health research by providing greater detail on both heterogeneity of treatment 
effects within racial groups and the complex causal processes that result in health 
disparities.29 By examining individual-level heterogeneity, the results of this study will 
provide more precise insight into who most (and least) benefits from the PCMH intervention. 
These results can guide policymakers in both in targeting PCMH outreach to specific 
populations and inform efforts to identify specific groups in need of enhanced or additional 
care.  
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Conceptual Model 
The conceptual model for this study (Figure 1) is adapted from the Andersen and 
Aday behavioral model for health service use.30 This model represents the quantity and 
quality of services accessed as a function of both the health care environment and population 
characteristics (predisposing characteristics, enabling resources, and need).This model 
represents how the key components of the PCMH will affect outcomes related to both quality 
and equity of care, an effect which is moderated by population characteristics. The key 
intervention in this conceptual model is the PCMH, which is composed of five core elements: 
comprehensiveness, affordability, accessibility, patient-centeredness, and focus on quality 
and safety. This model is designed to address barriers to receipt of high quality care including 
fragmented care, stigma towards mental health treatment, lack of knowledge, poor treatment 
adherence and self-management, and poor physician-patient communication. Because these 
barriers disproportionately affect racial/ethnic minorities, many believe that the PCMH 
should reduce disparities in quality of care.9,31 Finally, this model demonstrates that regional 
rates of PCMH adoption are not hypothesized to have any direct effect on quality or equity of 
care except via access to treatment in a PCMH. This assumption allows for the use of county 
PCMH adoption rates as an IV to control for selection bias. 
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Figure 1: Conceptual Model 
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CHAPTER 2: EFFECT OF PATIENT-CENTERED MEDICAL HOME 
ENROLLMENT ON RACIAL/ETHNIC DISPARITIES IN QUALITY OF CARE FOR 
ADULTS WITH DEPRESSION AND MULTIPLE CHRONIC CONDITIONS 
Overview 
Objective: Estimate the association between National Committee for Quality 
Assurance recognition of patient-centered medical homes (PCMHs) and racial/ethnic 
disparities in the quality of care for adults age 18-64 years with major depressive disorder 
(MDD) and comorbid medical conditions. 
Data sources: Secondary Medicaid claims data from 2008-2011 from Georgia, North 
Carolina, and Texas. 
Study design: Applying instrumental variables to account for differential selection 
into treatment, we used generalized estimating equations to determine the probability of 
receiving eight disease-specific quality measures for adults age 18-64 years with MDD and 
diabetes. We used a rank-and-replace method to measure disparities between racial groups, 
based on the Institute of Medicine definition. 
Data collection: Medicaid data merged with provider- and area-level data. 
Principal findings: PCMH enrollment was associated with an increase in the overall 
likelihood of receiving six of eight recommended services and a decrease in the likelihood of 
receiving any psychotherapy (4.94 percentage points, p<0.01) and retinal exams (5.51 
percentage points, p<0.05). Black-white and Hispanic-white disparities were each reduced 
for two measures. Although both groups improved, we also found that PCMH enrollment 
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exacerbated the Black-white disparity in adequate antidepressant use by 4.20 percentage 
points (p<0.01). 
Conclusions: While PCMH enrollment may improve overall quality of care, the effect 
is inconsistent across racial groups and not always associated with reductions in racial/ethnic 
disparities in quality. 
Background 
Persons with multiple chronic conditions (MCC) utilize health care services more 
frequently and access a wider range of services than the general population,1,2 making 
coordination of their care more difficult. Because mental health problems also exacerbate the 
disability associated with physical disorders and complicate their management,3 these 
coordination challenges make persons with co-occurring mental illnesses particularly 
vulnerable to suboptimal quality of care.1,4 
Further, racial/ethnic disparities in quality have been well-documented among 
persons with chronic disease and mental illness.5,6 Racial and ethnic minorities have less 
access to mental health services, are less likely to receive needed care, and are more likely to 
receive poor-quality care than their white counterparts.6 Although minority patients 
experience mental illness at approximately the same rate as whites, they are less likely to 
receive timely and appropriate treatment and are more likely to have unmet mental and 
physical health needs.6–9 One study examining the unmet need for mental health services 
among minorities found that for persons with major depressive disorder (MDD), 64% of 
Latinos, 69% of Asians, and 59% of African Americans did not access any past-year mental 
health treatment, compared with 40% of non-Hispanic whites.8 
The factors driving racial disparities in quality of care for this population are not 
completely understood, but cost of care, social stigma, provider discrimination, and 
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fragmented organization of services have been identified as barriers that may 
disproportionately prevent minority patients with mental illnesses from accessing quality 
care.6,10 Given that minority patients are more likely to seek mental health services in 
primary care than from a mental health specialist,7 understanding the potential for primary 
care models to these barriers and reduce health disparities in this population is critical.5,11,12 
The patient-centered medical home (PCMH) is a model of primary care that uses 
enhanced care coordination and disease management to improve outcomes, safety, system 
efficiency, and patient and provider experiences.13–15 The PCMH has been endorsed by a 
broad coalition of healthcare stakeholders, including all major national health plans, patient 
groups, and every major national physician organization.16,17 Several provisions of the 
Affordable Care Act also encourage PCMH models for populations with MCC and 
behavioral health needs, including enhanced federal funds for states implementing a variant 
of the model in their Medicaid programs.18 Thanks in part to these incentives, adoption of the 
PCMH model grew quickly; between 2009 and 2013 the number of PCMH initiatives 
increased from 26 to 114.19,20 By 2012, half of all states had implemented payment reforms 
encouraging expansion of the PCMH model for their Medicaid populations.20 
A growing body of literature demonstrates that the PCMH is effective for chronic 
care and that PCMH transformation is associated with improved clinical outcomes, overall 
quality of care,14,21 and patient experience of care.18  However, the literature also shows that 
the interventions classified as “medical homes” are heterogeneous.22 In an effort to 
standardize the definition of “medical home,” many organizations use a recognition program 
developed by the National Committee on Quality Assurance (NCQA) in 2008,23 which offers 
three recognition levels based on the number of PCMH elements adopted by a practice.18 
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Practices can obtain the required number of points for each recognition level from a flexible 
set of criteria, although there are certain “must-pass” elements required of all practices.24 
This variation in operational definition and changes in PCMH requirements over time make 
defining the PCMH challenging. 
Because the PCMH is being widely adopted and incentivized in Medicaid programs, 
assessing its effect on disparities is critical. This model is designed to address barriers to 
receipt of high quality care including fragmented care, lack of knowledge, poor treatment 
adherence and self-management, and poor physician-patient communication. Because these 
barriers disproportionately affect racial/ethnic minorities, the PCMH has the potential to 
reduce disparities in quality of care.25,26 Policymakers and providers involved in four state-
based PCMH initiatives in 2012-2013 reported in believing that the PCMH could reduce 
racial disparities by directly addressing the challenges faced by disadvantaged populations, a 
group that likely has the most room for improvement.26 Notably, the same study found that 
most respondents said that disparities were not part of the considerations that motivated the 
design of the PCMH initiative.26 
There is some evidence to suggest that overall quality improvement initiatives like the 
PCMH will improve outcomes for racial minorities and potentially reduce racial/ethnic 
disparities even if they are not specifically designed to do so.10 In a large trial of quality 
improvement for depression in older adults, a collaborative care intervention significantly 
improved care for Black, Hispanic/Latino, and white patients similarly.27 A study of two 
quality improvement interventions for depression found that improvements in quality were 
greater for Hispanic/Latino and Black patients than they were for whites.28 These studies 
suggest that racial/ethnic minority patients may benefit from quality of care interventions, 
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even in the absence of substantial cultural adaptations of the intervention, and that some 
interventions may disproportionately benefit minority patients.27 
Several studies have documented disparities in access to the PCMH.29–31 For 
example, the Commonwealth Fund 2006 Health Care Quality Survey found that among all 
adults with a chronic condition, Hispanics were the least likely to have medical homes (20%) 
compared with whites (32%), Asian Americans (32%), and African Americans (34%).31 
However, empirical evidence about the effects of this model on racial disparities in quality 
outcomes is limited; racial/ethnic disparities in quality are not well-documented or widely 
evaluated in PCMH initiatives.14,26,32 Those studies that do examine the effect of the PCMH 
on racial disparities report mixed results.22 Some studies have found that the PCMH model 
reduces or eliminates racial disparities in quality of care metrics such as preventive care 
reminders, cholesterol testing, and cancer screenings.31 However, other studies found varying 
effects among racial/ethnic groups17,29,33,34 and some found no effect on disparities.35 
This study investigates the effects of NCQA-recognized PCMH practices on racial 
disparities in quality among patients with comorbid depression and chronic physical 
conditions. The present study focuses on how the key components of the PCMH will affect 
outcomes related to both quality and equity of care, an effect that is moderated by 
predisposing characteristics such as race/ethnicity, socioeconomic status, age, and sex. 
Methods 
Setting 
This analysis includes Medicaid claims from 2008-2011 in North Carolina, Georgia, 
and Texas. This study focuses on NCQA-recognized PCMHs because many existing 
Medicaid PCMH initiatives utilize incentive structures that base payments on NCQA 
recognition and over 50 payers nationwide offer enhanced reimbursement for NCQA-
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recognized practices.36 The NCQA’s PCMH recognition standards were first implemented in 
2008, therefore these data reflect the early stages of the program. During the study period, 
North Carolina was the only state in our sample with a state-developed medical home 
program.37 The state’s Medicaid PCMH program, Community Care of North Carolina 
(CCNC), does not require participating providers to attain NCQA recognition, but does offer 
resources and support for practices seeking recognition. During this period, medical home 
initiatives in Georgia and Texas were largely supported by private partnerships.38,39  
Data/sample 
This study uses a novel dataset constructed from several administrative data sources. 
First, 2008-2011 Medicaid Analytic eXtract (MAX) claims data from three states (NC, GA, 
TX) were merged with the data from the National Plan and Provider Enumeration System 
(NPPES) which contains National Provider Identifiers (NPIs) from practicing providers and 
organizations, including deactivated NPIs. The NPPES contains information on several 
provider characteristics, including gender, provider type, state, and Medicaid billing 
identifiers. These data were then combined with NCQA PCMH recognition data, which 
contain information on PCMH characteristics such as date, duration, and level of recognition. 
County supply of mental health professionals was measured using data from the Area Health 
Resource File.40 Finally, socioeconomic status variables were measured at the county level 
using the U.S. Census Bureau’s Small Area Income and Poverty Estimates.41 
The study population includes Medicaid beneficiaries who are not dually enrolled in 
Medicare, ages 18-64 years, with MDD and at least one other chronic condition. MDD was 
identified using ICD-9 codes 296.2, 296.3, 300.4, and 311. Subgroup analyses were 
conducted for individuals with diabetes (Type I or Type II) because it a condition that is 
highly prevalent in Medicaid populations.42,43 Additionally, clear evidence indicates that 
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comorbid depression interferes with diabetes self-management, 44and studies have shown that 
MDD is also an independent risk factor for Type II diabetes.45 To avoid “rule-out” diagnoses 
and/or errors in coding we used strict definitions of MDD and diabetes, defined as having at 
least one inpatient diagnosis or at least two outpatient or emergency department diagnoses 
during a single year in the study period, and at least one claim for the condition in the current 
year. We excluded individuals with serious mental illnesses such as schizophrenia or bipolar 
disorder because specialty providers are more likely to serve as the primary point of contact 
with the healthcare system for this population.46 
Key Measures 
Key outcomes included disease-specific quality indicators for MDD and diabetes 
derived from Medicaid claims (see Table 1 for full definitions). Quality measures were 
selected based on recommended core quality measures for the PCMH,47 the Centers for 
Medicare and Medicaid Services 2016 core set of adult quality measures for Medicaid,48 and 
the 2011 Healthcare Effectiveness Data and Information Set (HEDIS). 
Any antidepressant use, receipt of any psychotherapy, and all four diabetes measures 
were measured at the person-year level. Clinical guidelines specify that use of 
antidepressants or psychotherapy should be based on clinical circumstances such as severity 
and complex psychosocial situations.49 Because this information was not available in claims 
data, we measured the likelihood that beneficiaries with MDD received any psychotherapy or 
any antidepressant prescription. While either treatment modality would be considered 
guideline-concordant, these measures represent a minimum quality standard.50,51 
Given the episodic nature of MDD, we also constructed an episode-level variable for 
minimally adequate antidepressant use in addition to the calendar-year depression measures. 
In episodic analyses, we assessed the HEDIS antidepressant management measure for 
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effective acute phase treatment, defined as the likelihood that beneficiaries received at least 
84 days of antidepressants during an acute episode.52 We focused on the acute phase of 
treatment because it is typically the period of most intensive treatment,50 and there are clear 
guidelines for antidepressant usage during this phase.52 An acute episode was initiated by two 
MDD outpatient services on different dates or by initiation of an antidepressant prescription. 
We required a period of at least three months without MDD claims before the initiation of a 
new episode. The acute phase of an episode was considered to have ended after either 90 
days of no MDD services or antidepressants or 120 days after the start of the episode.50 
Because we were unable to observe prescriptions received during inpatient hospitalizations, 
we adjusted for inpatient episodes by assuming that patients received dispensed medication 
during their hospitalization and resumed their outpatient medications upon discharge. 
The primary explanatory variable was a binary indicator of yearly engagement in an 
NCQA-certified PCMH. In 2008, NCQA PCMH recognition criteria consisted of nine 
standards: access and communication; patient tracking and registry functions; care 
management; self-management support; electronic prescribing; test tracking; referral 
tracking; performance reporting and improvement; and advanced electronic communications. 
Additionally, there were five “must-pass” elements to achieve level 1 recognition and ten 
required for levels 2 and 3. 
We identified primary care providers using provider taxonomy codes for internal 
medicine, family medicine, pediatrics, general practice, ambulatory clinics, nurse 
practitioners, and physician assistants. Patients were attributed to a primary care provider 
using the “plurality rule” commonly applied by the Centers for Medicare and Medicaid 
Services, especially for attributing beneficiaries to Accountable Care Organizations.53 Under 
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this method, a beneficiary’s primary care provider is defined as the provider that delivers the 
plurality of the beneficiary’s non-hospital evaluation and management (NH-E&M) visits.54 In 
the event that a beneficiary received the same number of services from two providers, they 
were attributed to the most recent provider.54 Because this study is focused on a population 
with MDD, we modified this method by attributing beneficiaries first to the primary care 
provider where they received the plurality of depression-related NH E&M claims. If a 
beneficiary did not have a depression-related NH E&M claim with a primary care provider, 
they were then attributed to the primary care provider where they received the plurality of 
general NH E&M services. For example, if a beneficiary had NH E&M claims from three 
providers but saw only one of these providers for claims related to depression, the 
beneficiary was attributed to the provider whom they saw for a depression-related concern. 
We conducted sensitivity analyses defining PCMH enrollment as having any claim with an 
NCQA recognized PCMH provider during a given year. A provider’s PCMH status was 
determined using NCQA recognition data. 
Beneficiary-level covariates derived from claims included age, sex, number of 
additional chronic comorbidities, number of Medicaid-enrolled months and rurality. Chronic 
conditions were identified using the Agency for Healthcare Research and Quality’s Chronic 
Condition Indicator software, which defines chronic conditions as lasting at least 12 months 
and causing limitations on self-care or resulting in need for ongoing medical intervention.55 
Rurality was measured in three categories (metropolitan, metropolitan-adjacent, and rural) 
using simplified county-level Rural-Urban Continuum Codes.56 Provider-level covariates 
included Federally Qualified Health Center or Rural Health Center status, and sex. County-
level supply of mental health professionals was measured using county supply of 
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psychiatrists and Mental Health Professional Shortage Area (HPSA) status (full or partial). 
Finally, county-level socioeconomic characteristics were measured using percent of the 
population under poverty and median income. 
Because of concerns about the endogeneity of participating in a PCMH, we 
constructed two instrumental variables based on county rates of PCMH adoption. First, the 
ratio of county PCMH adoption was defined as the number of unique PCMH providers in a 
county divided by the total number of Medicaid primary care providers, as measured by 
NCQA PCMH recognition data and the Area Health Resource File. The second instrument 
was a similar county-level rate of NCQA medical home practices to all primary care 
providers, but both the numerator and denominator were conditional on the provider NPI 
appearing in Medicaid MAX claims during the study period. 
Defining & Measuring Disparities 
This study employs the definition of disparities described in the 2002 Institute of 
Medicine (IOM) report “Unequal Treatment: Confronting Racial and Ethnic Disparities in 
Health Care.” The IOM defines a racial disparity in health care as “racial or ethnic 
differences in the quality of health care that are not due to access-related factors or clinical 
needs, preferences, and appropriateness of intervention.’’57 Under this definition, the simple 
unadjusted difference in means or rates between racial groups does not constitute a 
healthcare disparity.57,58 Rather, measuring a disparity requires separating out “differences” 
that are driven by underlying health status or preference from those that represent true 
“disparities” that are driven by healthcare systems factors or discrimination.57 Another 
distinguishing feature of this definition is that it includes the effects of mediating factors 
(other than health status and preferences), such as variables associated with geography or 
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socioeconomic status.57 Therefore, implementing this definition requires adjusting for health 
status, but not other factors explaining differences in service use or expenditures.58 
While measuring differences in outcomes can be accomplished by comparing the 
observed sample means between whites and minority groups, measuring disparities under the 
IOM definition requires generating counterfactual predictions of the outcomes that minority 
groups would experience if their health status were identical to their white counterparts. To 
implement this counterfactual, we estimate racial disparities as follows: 1) with non-Hispanic 
whites as a reference group, fit a model describing relationships between quality/utilization 
and health status, race, and other characteristics, 2) using a rank and replace method, 
transform the distributions of health status variables (age, gender, and number of 
comorbidities) for minority groups to be the same as those of non-Hispanic whites, while 
leaving other variables unchanged, creating a counterfactual minority subgroup with 
distributions identical to the white subgroup 3) calculate predictions using the coefficients 
from the initial models and the transformed/counterfactual health status variables for 
minority groups, and 4) aggregate predictions by racial group to estimate disparities.58 
Variance estimates for these aggregated predictions were obtained via 500 bootstrap 
iterations. 
Analytic Methods 
This analysis uses generalized estimating equations (GEE) with a binomial family 
and logit link function selected based on the probability distributions of the dependent 
variables. We examined independent, exchangeable, and unstructured correlation structures; 
an independent correlation structure was selected based on the quasi-likelihood under the 
independence model criterion (QIC).59 The functional form of the covariates was also 
selected based on QIC. We examined age as a quadratic variable and interactions between 
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race and medical home status, median income, percent under poverty, and gender. Only the 
quadratic form of age improved model fit. 
Because PCMH enrollment is non-random and therefore likely subject to selection 
bias, we used an instrumental variable (IV) approach. To address this differential selection, 
we used two-stage residual inclusion (2SRI). The first stage 2SRI model uses a logit model to 
regress PCMH enrollment on the instruments and other covariates: 
Equation 1: PCMH_enrollmentit = β0 + β1*PCMH_ratect + β2*Xipct+ εipct 
where X represents a vector of covariates and i, p, and c represent individual, provider, and 
county level variables and t is the time-period (year). The residuals (predicted_residuals) 
from this model were included in the second stage GEE equation: 
Equation 2: Yit= β0 + β1*PCMH_enrollmentit + β2*Xipct + β3*(predicted_residuals) + εipct 
Where Y represents a set of binary dependent variables, defined as the receipt of each 
quality indicator. 
Average marginal effects for the overall estimates were obtained using predictive 
margins. Because the second stage of the 2SRI model does not account for the estimated 
residuals included from the first stage, we used bootstrapping (500 replicates) to obtain the 
most precise standard errors. Bootstrap replicates were clustered at the beneficiary level to 
account for repeated observations over time. In the disparities models, predicted probabilities 
were obtained using the methods described above and standard errors were obtained via 
bootstrapping (500 replicates) clustered at the beneficiary level. 2SRI models yield estimates 
that should be interpreted within a Local Average Treatment Effect (LATE) context. All 
analyses were performed using Stata (Version 13). 
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We conducted several tests on our instruments, including tests of exogeneity using 
the Durbin and Wu–Hausman tests,60 tests of instrument strength,61 and over‐identification.62 
The instruments were uniformly strong, with F-statistics of the joint significance of the two 
instruments ranging from 1048.92 to 4029.4. The correlation between the instruments was 
0.44, suggesting that although the two measure similar constructs, they are capturing 
different information and are both appropriate for inclusion in these models. PCMH 
enrollment was determined to be endogenous in all 8 models. The instruments pass the 
overidentification test for 5 of the 8 models; the calendar-year psychotherapy, antidepressant, 
and combined psychotherapy/antidepressant models did not pass. However, there is some 
controversy about overidentification tests in recent literature; while they are generally 
discussed as tests of excludability, they are in fact joint tests of excludability and 
homogeneity of treatment effects. Therefore, instruments that are excludable may be rejected 
due to local average treatment effects.63,64 
Results 
The final sample (Table 2) consisted of 310,906 person-years contributed by 191,565 
unique individuals. Approximately 1.6% of person-years were accounted for by PCMH 
enrollees. PCMH enrollees were more likely to be Black (39.2% versus 30.1% among non-
enrollees, p<0.001), and less likely to live in rural areas (p<0.001). In unadjusted 
comparisons (Table 3), PCMH enrollees were significantly (p<0.01) more likely to receive 
all recommended services except for yearly psychotherapy and retinal exams. 
Major Depression Outcomes 
In the calendar-year depression analyses (Table 4), we found that PCMH enrollment 
was associated with a 4.88 percentage point increase in the overall receipt of any depression 
treatment, whether psychotherapy or antidepressants, among beneficiaries with MDD 
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(p<0.01). This improvement was driven primarily by antidepressant use; PCMH enrollees 
saw a 5.94 percentage point higher rate of receipt of any antidepressants (p<0.01), but also a 
4.94 percentage point overall lower rates of psychotherapy (p<0.01). In the acute episodic 
depression analyses, PCMH enrollment was associated with a 2.85 percentage point higher 
probability of receiving minimally adequate antidepressants (p<0.05). In fully adjusted 
models, Black and Hispanic/Latino beneficiaries were 3.31 and 3.69 percentage points more 
likely to receive psychotherapy than their white counterparts (p<0.01), but 14.30 and 5.46 
percentage points less likely to receive antidepressants (p<0.01). 
In disparities models for depression outcomes (Table 5), Black and Hispanic/Latino 
beneficiaries had slightly higher predicted probabilities of receiving annual psychotherapy 
than white beneficiaries in both the non-PCMH and PCMH groups (50.9% and 41.1% 
respectively, compared to 39.6% for whites), and this pattern persisted among PCMH 
enrollees. However, this effect was heterogeneous across racial groups: PCMH enrollment 
was associated with a lower predicted probability of receiving any psychotherapy for white 
and Black enrollees, and a small increase for Hispanic/Latino enrollees. PCMH enrollment 
significantly reduced Black-white and Hispanic-white disparities in calendar-year 
antidepressant use by 0.90 percentage points (p<0.05) and 9.72 percentage points (p<0.01), 
respectively. PCMH enrollment was also associated with a 6.81 percentage point reduction in 
Hispanic-white disparities (p<0.01) in receipt of either calendar-year measure. Finally, in 
acute episodic analyses, PCMH enrollment was associated with a 4.20 percentage point 
increase in Black-white disparities (p<0.01) and had no statistically significant association 
with Hispanic-white disparities. 
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Diabetes Outcomes 
Among patients with diabetes(Table 6), PCMH enrollment generally increased 
overall receipt of recommended diabetes services:  an 11.70 percentage point increase in the 
overall probability of receiving of a lipids panel (p<0.01), a 14.00 percentage point increase 
in the probability of an A1c test (p<0.01), and a 7.53 percentage point increase in the 
likelihood of receiving attention for nephropathy (p <0.01). Being a PCMH enrollee was 
associated with a 5.51 percentage point decrease in the likelihood of receiving a retinal exam 
(p<0.05). Before rank-and-replace adjustment, Hispanic/Latino beneficiaries were 
significantly more likely to receive all diabetes services than their white counterparts. Black 
beneficiaries were more likely to receive eye exams and attention for nephropathy, but 
slightly less likely to receive lipids testing. There was no significant association between 
Black race and A1c testing in the fully-adjusted models. 
In IOM-adjusted disparities models for diabetes (Table 7), Black beneficiaries not 
enrolled in a PCMH were 2.27 percentage points less likely to receive A1c testing (p<0.01), 
and this disparity was eliminated among PCMH enrollees. Statistically significant black-
white disparities also existed for both receipt of lipids testing and retinal exams. Among 
PCMH enrollees, the disparity in lipids testing was reduced from 7.36 percentage points to 
3.71 percentage points and the disparity in retinal exams was reduced from 6.45 percentage 
points to 5.70 percentage points, however the reduction was not statistically significant for 
either measure. There were no statistically significant Black-white disparities in attention for 
nephropathy. Hispanic/Latino beneficiaries had higher rates of A1c testing and this 
advantage persisted among PCMH enrollees. There were no statistically significant Hispanic-
white disparities for either treatment group in receipt of lipids panels or attention for 
nephropathy. A statistically significant Hispanic-white disparity existed in the PCMH group 
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for retinal exams, but not for the non-PCMH group, suggesting that disparities were 
exacerbated among PCMH enrollees. 
Sensitivity Analyses 
For most measures, including annual receipt of antidepressants, minimally adequate 
episodic antidepressant use, A1c testing, and retinal exams, sensitivity analyses defining 
PCMH attribution as any claim with an NCQA-recognized provider produced results similar 
to the primary analyses in direction and significance, though the effect sizes were generally 
smaller in magnitude. An exception to this trend was the annual receipt of psychotherapy, 
where the effect of PCMH enrollment was almost twice as large as the primary analyses. Due 
to the larger decrease in receipt of psychotherapy, this definition of PCMH enrollment was 
also associated with a 2.02 percentage point decrease in receipt of either psychotherapy or 
antidepressants (p<0.01). 
Discussion 
We found that PCMH enrollment increased the likelihood of receiving six of eight 
recommended services. This finding is consistent with the literature, which suggests that the 
PCMH model improves quality of care in Medicaid populations.18,21 The two exceptions to 
this trend were psychotherapy and retinal exams (for beneficiaries with diabetes). These 
exceptions may exist because unlike the other quality measures, these two services cannot be 
provided in primary care. However, both psychotherapy and antidepressants are considered 
appropriate treatments for antidepressants and we found that despite the decrease in receipt 
of psychotherapy, receipt any calendar-year depression treatment increased among PCMH 
enrollees. 
However, in IOM-adjusted disparities analyses, the effects of the PCMH varied 
across racial groups. Some providers and policymakers believe that the PCMH should 
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improve outcomes for all racial groups, but that minority groups will benefit more because 
they have the most room for improvement.26 Overall, our findings do not support this belief; 
we only see this pattern in Black-white disparities in any antidepressant use and A1c testing 
and Hispanic-white disparities in any antidepressant use and use of either psychotherapy or 
antidepressants; each reflecting only two of eight possible quality measures. In other cases 
(e.g., Black-white disparities in adequate episodic antidepressant use), PCMH enrollment 
improves the outcome for both the white and minority groups, but the disparity between the 
two is slightly exacerbated. 
Notably, we found that minority patients received better quality of care on several 
measures, especially for Hispanic/Latino beneficiaries. In most cases these advantages 
persisted between the non-PCMH and PCMH groups. One possible explanation for this trend 
is the fact that this sample is limited to individuals enrolled in Medicaid; previous studies 
have found that Hispanic-white disparities are driven in large part by significant disparities in 
health insurance coverage.9,66 Another possible factor is that these analyses do not control for 
English fluency or language concordance between patient and provider.67 
Limitations 
This study has several limitations. First, individual-level SES data are not available in 
Medicaid claims data; these analyses instead use county-level measures of SES. Although 
individual-level SES data is preferable for studying racial/ethnic disparities, area-based 
measures are often used to adjust for SES in studies using administrative data and perform as 
well as more complex composite measures of area-level economic deprivation.68 Second, 
PCMH recognition level is not necessarily indicative of the services that a practice provides. 
Non-PCMH primary care practices may be engaging in many of the same activities as 
NCQA-recognized PCMHs but may not seek recognition due to financial or other concerns. 
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Third, Medicaid claims may underreport retinal exams because communities often offer free 
eye exams that do not appear in claims. However, this underreporting would not 
differentially affect enrollees linked to PCMH and non-PCMH practices. Finally, there are no 
measures of patient perspective or experience of care are not available in administrative data. 
Given that patient preference is a crucial aspect of the IOM definition of disparities, future 
research on the effect of the PCMH on racial disparities should take detailed patient 
preference variables into account, perhaps using survey data. 
Conclusions 
These findings show that while the PCMH model may improve overall quality of 
care, the effect is not necessarily consistent across racial groups. Further, PCMH enrollment 
not always associated with a reduction in racial/ethnic disparities in quality of care. This 
suggests that while the PCMH has potential to reduce disparities, implementing a PCMH 
model alone may not be sufficient to reduce racial inequities in quality of care. Providers or 
policymakers should consider racial/ethnic disparities explicitly when designing, 
implementing, and evaluating PCMH programs.   
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Table 1: Disease-Specific Dependent Variables 
Variable Definition 
Calendar-
Year 
Acute 
Episode 
Depression 
Antidepressant 
use 
Receipt of any antidepressant prescriptions X  
Receipt of at least 84 days of antidepressants during 
a 120-day episode. 
 X 
Psychotherapy Receipt of any group/individual psychotherapy X  
Any MDD 
treatment 
Receipt of any antidepressant prescriptions or 
group/individual psychotherapy  
X  
Diabetes 
A1C Testing Percent of diabetic patients receiving A1C testing X  
LDL-C Testing Percent of diabetic patients receiving an LDL–C test X  
Retinal exam Percent of diabetic patients receiving a retinal exam X  
Nephropathy 
screening 
Percent of diabetic patients screened for 
nephropathy 
X  
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Table 2: Summary Statistics  
 N(%) or Mean(SD) 
 Total Non-PCMH PCMH 
N (Person-Years) 310,906 306,040 (98.40%) 4,866 (1.60%) 
Diabetes 82,501 (26.50%) 81304 (26.60%) 1,197 (24.60%) 
Race/ethnicity    
     White 156,039 (50.20%) 153,529 (50.20%) 2,510 (51.60%) 
      Black 94167 (30.30%) 92259 (30.10%) 1908 (39.20%) 
      Hispanic/Latino 37516 (12.10%) 37329 (12.20%) 187 (3.80%) 
Female Beneficiary 246694 (79.30%) 242765 (79.30%) 3929 (80.70%) 
Age 40.82 (13.57) 40.83 (13.57) 40.15 (13.35) 
Months of Medicaid enrollment 10.771 (2.40) 10.77 (2.40) 10.801 (2.32) 
Chronic comorbidities  5.23 (4.31) 5.23 (4.31) 5.32 (4.26) 
County % Under Poverty 18.80 (5.72) 18.81 (5.75) 18.16 (3.63) 
County median income 
43,726.33 
(9,316.43) 
43,702.24 
(9,351.32) 
45,240.96 
(6,595.7111) 
Rurality    
     Rural: MSA-adjacent 65,664 (21.10%) 65,280 (21.30%) 384 (7.90%) 
     Rural  17,363 (5.60%) 17,292 (5.70%) 71 (1.50%) 
Mental Health Professional Shortage 
Area (HPSA) 
   
     Whole county 120,531 (38.80%) 119,977 (39.20%) 554 (11.40%) 
     Partial county  113,380 (36.50%) 110,821 (36.20%) 2,559 (52.60%) 
County Supply of Psychiatrists  49.70 (89.47) 49.43 (89.45) 66.47 (88.62) 
State    
     Georgia 84,958 (27.30%) 84661 (27.70%) 297 (6.10%) 
     North Carolina 137,198 (44.10%) 132,995 (43.50%) 4,203 (86.40%) 
     Texas 88,750 (28.50%) 88,384 (28.90%) 366 (7.50%) 
Year    
     2008 63,713 (20.50%) 63,713 (20.80%) 0 (0.0%) 
     2009 83,764 (26.90%) 83,674 (27.30%) 90 (1.80%) 
     2010 94,296 (30.30%) 92,649 (30.30%) 1,647 (33.80%) 
     2011  69,133 (22.20%) 66,004 (21.60%) 3,129 (64.30%) 
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Table 3: Unadjusted Rates of Quality Metrics 
 
Non-PCMH 
N(%) 
PCMH 
N(%) 
p-value 
(t-test) 
Depression 
Calendar Year    
     Any psychotherapy 109,510 (40.6%) 1,721 (39.3%) 0.066 
     Any antidepressants 159,948 (59.4%) 3,174 (72.4%) <0.001 
     Psychotherapy or antidepressants 203,058 (75.4%) 3,728 (85.1%) <0.001 
     N 269,460 4,383  
Acute Episode    
     Min. antidepressants 40,297 (24.0%) 1,035 (33.6%) <0.001 
     N 167,910 3,076  
Diabetes 
     A1c testing 52,963 (65.0%) 918 (76.7%) <0.001 
     Retinal exam 26,780 (32.9%) 346 (28.9%) 0.004 
     Lipids panel 40,450 (49.7%) 751 (62.8%) <0.001 
     Attn for nephropathy 24,151 (29.6%) 489 (40.9%) <0.001 
     N 81.483 1,197  
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Table 4: Average Marginal Effect of PCMH Enrollment on Depression Outcomes 
 Calendar Year Acute Episode 
 Any 
Psychotherapy 
Any 
Antidepressants 
Psychotherapy or 
Antidepressants 
Adequate 
Antidepressants 
PCMH Enrollment -0.0494*** 0.0594*** 0.0488*** 0.0285** 
 (0.0105) (0.0108) (0.00985) (0.0123) 
Race     
     Black 0.0331*** -0.143*** -0.0735*** -0.153*** 
 (0.00295) (0.00291) (0.00258) (0.00250) 
     Hispanic/Latino 0.0369*** -0.0546*** -0.0221*** -0.0801*** 
 (0.00464) (0.00441) (0.00354) (0.00478) 
Chronic Conditions -0.00486*** 0.00937*** 0.000994*** 0.00778*** 
 (0.000287) (0.000280) (0.000239) (0.000298) 
Rurality     
     Non-metro (adjacent 
to urban area) 
-0.000142 
(0.00308) 
-0.0101*** 
(0.00300) 
-0.00803*** 
(0.00267) 
-0.00945*** 
(0.0318) 
     Non-metro (non-
urban adjacent) 
-0.0398*** 
(0.00497) 
-0.0187*** 
(0.00494) 
-0.0364*** 
(0.00453) 
-0.000935 
(0.00524) 
Beneficiary age -0.00366*** -0.0 0159*** -0.00341*** 0.00199*** 
 (8.58e-05) (8.53e-05) (7.65e-05) (8.84e-05) 
Female Beneficiary 0.00930*** 0.0594*** 0.0402*** 0.0325*** 
 (0.00257) (0.00252) (0.00225) (0.00267) 
Months of Medicaid 
Enrollment  
0.0166*** 
(0.000455) 
0.0112*** 
(0.000423) 
0.0148*** 
(0.000352) 
0.00926*** 
(0.000518) 
FQHC -0.0111*** 0.0532*** 0.0333*** 0.00826** 
 (0.00378) (0.00356) (0.00305) (0.00408) 
RHC -0.0283*** 0.0364*** 0.0220*** 0.0296*** 
 (0.00477) (0.00453) (0.00383) (0.00512) 
Female Provider 0.00529** 0.0442*** 0.0341*** 0.0238*** 
 (0.00255) (0.00245) (0.00213) (0.00273) 
County Percent Under 
Poverty 
0.00156*** 
(0.000364) 
-0.00392*** 
(0.000347) 
-0.00119*** 
(0.000297) 
-0.00334*** 
(0.000401) 
     
County Median Income 1.62e-06*** -1.79e-06*** -2.96e-07 -9.14e-07*** 
 (2.33e-07) (2.24e-07) (1.96e-07) (2.50e-07) 
County # of 
Psychiatrists 
0.000183*** 
(1.51e-05) 
8.87e-05*** 
(1.41e-05) 
0.000127*** 
(1.16e-05) 
-1.65e-05 
(1.79e-05) 
Mental Health HPSA:     
     Whole county 0.0136*** -0.00392 -0.000839 0.000480 
 (0.00309) (0.00301) (0.00269) (0.00324) 
     Partial county 0.0234*** -0.0190*** -0.00183 -0.00824*** 
 (0.00277) (0.00275) (0.00248) (0.00289) 
State     
     North Carolina -0.0261*** 0.0775*** 0.0416*** 0.0361*** 
 (0.00295) (0.00279) (0.00229) (0.00321) 
     Texas -0.155*** -0.159*** -0.155*** -0.0767*** 
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 Calendar Year Acute Episode 
 Any 
Psychotherapy 
Any 
Antidepressants 
Psychotherapy or 
Antidepressants 
Adequate 
Antidepressants 
 
(0.00334) (0.00345) (0.00319) (0.00350) 
 
Year     
     2010 0.00154 -0.0251*** -0.0122*** -0.0106*** 
 (0.00250) (0.00241) (0.00209) (0.00260) 
     2011 -0.00150 -0.00189 0.00214 0.0355*** 
 (0.00284) (0.00277) (0.00247) (0.00311) 
Pearson Residual -0.0494*** 0.0594*** 0.0488*** 0.00188 
 (0.00982) (0.0101) (0.00872) (0.00226) 
Bootstrapped standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Table 5: Comparison of Predicted Probabilities and Disparities Changes for Depression 
Outcomes 
 White Black Disparity 
Hispanic 
/Latino Disparity 
Any Psychotherapy 
(Annual)      
     Non PCMH 0.396*** 0.509*** -0.113*** 0.411*** -0.0152*** 
 (0.00170) (0.00248) (0.00298) (0.00352) (0.00396) 
     PCMH 0.372*** 0.468*** -0.0957*** 0.450*** -0.0774*** 
 (0.00770) (0.00825) (0.00423) (0.0112) (0.00844) 
     Δ Disparity   0.0173***  -0.0623*** 
   (0.00321)  (0.00742) 
Any Antidepressants 
(Annual)      
     Non PCMH 0.666*** 0.525*** 0.141*** 0.442*** 0.224*** 
 (0.00160) (0.00259) (0.00307) (0.00386) (0.00423) 
     PCMH 0.781*** 0.650*** 0.131*** 0.655*** 0.126*** 
 (0.00636) (0.00819) (0.00457) (0.0124) (0.0101) 
     Δ Disparity   -0.00903**  -0.0972*** 
        (0.00381)  (0.00944) 
Psychotherapy or 
Antidepressants 
(Annual)      
     Non PCMH 0.792*** 0.774*** 0.0178*** 0.693*** 0.0993*** 
 (0.00143) (0.00214) (0.00253) (0.00333) (0.00361) 
      PCMH 0.873*** 0.851*** 0.0218*** 0.842*** 0.0311*** 
 (0.00497) (0.00583) (0.00330) (0.00872) (0.00719) 
     Δ Disparity   0.00399  -0.0681*** 
   (0.00295)  (0.00711) 
Adequate 
Antidepressants 
(Episodic)      
     Non PCMH 0.274*** 0.120*** 0.154*** 0.105*** 0.169*** 
 (0.00167) (0.00145) (0.00215) (0.00213) (0.00267) 
     PCMH 0.375*** 0.179*** 0.196*** 0.198*** 0.177*** 
 (0.00942) (0.00606) (0.00540) (0.0106) (0.00923) 
     Δ Disparity   0.0420***  0.00763 
   (0.00501)  (0.00853) 
Bootstrapped Standard Errors in Parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Table 6: Average Marginal Effect of PCMH Enrollment on Diabetes Outcomes 
 Lipids A1c Retinal Exam 
Attn for 
Nephropathy 
PCMH Enrollment 0.117*** 0.140*** -0.0551** 0.0753*** 
 (0.0217) (0.0201) (0.0252) (0.0260) 
Race     
     Black -0.0194*** 0.00596 0.0218*** 0.0344*** 
 (0.00483) (0.00537) (0.00454) (0.00506) 
     Hispanic/Latino 0.0341*** 0.0475*** 0.0445*** 0.0690*** 
 (0.00731) (0.00831) (0.00729) (0.00744) 
Chronic Conditions 0.00675*** 0.0103*** 0.0145*** 0.0129*** 
 -0.00038 (-0.000409 -0.000367 -0.000361 
Rurality     
     Non-metro (adjacent to 
urban area) 
-0.00906* 
(-0.00506) 
-0.00772 
(-0.00527) 
-0.0015 
(-0.00516) 
-0.0217*** 
(-0.00511) 
     Non-metro (non-adjacent to 
urban area) 
-0.0553*** 
(-0.00837) 
-0.0457*** 
(-0.00853) 
-0.0336*** 
(-0.00806) 
-0.0766*** 
(-0.0078) 
Beneficiary age -0.00182*** 
(-0.000194) 
-0.00339*** 
(-0.000209) 
2.43E-05 
(-0.000205) 
-0.00232*** 
(-0.000196) 
Female Beneficiary 0.00445 -0.000305 0.0170*** -0.00725* 
 (-0.00415) (-0.00436) (-0.00425) (-0.00424) 
Months of Medicaid Eligibility  0.0243*** 0.0190*** 0.0144*** 0.0103*** 
 -(0.000884) (-0.000876) (-0.00101) (-0.00097) 
FQHC 0.0268*** 0.0376*** 0.0405*** 0.0524*** 
 (-0.00605) (-0.00622) (-0.00644) (-0.00643) 
RHC 0.0670*** 0.0797*** 0.141*** 0.00633 
 (-0.00776) (-0.00786) (-0.00862) (-0.0082) 
Female Provider 0.0631*** 0.0867*** 0.0338*** 0.0674*** 
 (-0.00444) (-0.00449) (-0.00472) (-0.00469) 
County Percent Under Poverty 0.00144** -0.00271*** 0.00288*** -0.00017 
 (-0.000592) (-0.000608) (-0.000582) (-0.000581) 
County Median Income 8.46e-07** -1.36e-06*** -1.10e-06*** -5.05E-07 
 (-4.06E-07) (-4.19E-07) (-4.16E-07) (-4.03E-07) 
County # of Psychiatrists -8.27e-05*** -1.24E-05 -5.76e-05** 6.30e-05*** 
 (-2.46E-05) (-2.68E-05) (-2.46E-05) (-2.36E-05) 
Mental Health HPSA     
     Whole county 0.0283*** 0.00375 -0.0261*** -0.00397 
 (-0.00529) (-0.00546) (-0.00547) (-0.00538) 
     Partial county 0.00451 0.00890* -0.0196*** 0.00751 
 (-0.0047) (-0.00509) (-0.00505) (-0.004930 
State (Referent state = 
Georgia) 
    
     North Carolina 0.396*** 0.138*** 0.0795*** 0.0548*** 
 (-0.00466) (-0.00521) (-0.00478) (-0.00469) 
     Texas 0.512*** 0.203*** 0.115*** 0.101*** 
 (-0.00567) (-0.00611) (-0.00598) (-0.00597) 
Year (Referent year=2009)     
     2010 -0.0170*** -0.00399 0.0113*** -0.00383 
 
(-0.00415) (-0.00432) (-0.00437) (-0.00419) 
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 Lipids A1c Retinal Exam 
Attn for 
Nephropathy 
     2011 -0.0696*** -0.0527*** -0.108*** -0.0250*** 
 (-0.00483) (-0.00501) (-0.00476) (-0.00482) 
Pearson Residuals -0.00475* -0.00656* 0.0152*** 0.00474* 
 (-0.00272) (-0.00346) (-0.00477) (-0.002460) 
Bootstrapped standard errors in parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Table 7: Comparison of Predicted Probabilities and Disparities Changes for Diabetes 
Outcomes 
 White Black Disparity Hispanic/Latino Disparity 
Lipids Panel      
     Non PCMH 0.472*** 0.398*** 0.0736*** 0.686*** -0.214 
 (0.00351) (0.00526) (0.00621) (0.00675) (0.00752) 
     PCMH 0.630*** 0.593*** 0.0371*** 0.651*** -0.0216 
 (0.0164) (0.0167) (0.0131) (0.0262) (0.0237) 
     Δ Disparity   -0.0365  0.193*** 
   (0.0125)  (0.0228) 
A1c Testing      
     Non PCMH 0.619*** 0.597*** 0.0227*** 0.736*** -0.117*** 
 (0.00370) (0.00557) (0.00652) (0.00635) (0.00746) 
     PCMH 0.752*** 0.760*** -0.00876 0.797*** -0.0454*** 
 (0.0150) (0.0136) (0.00922) (0.0160) (0.0131) 
     Δ Disparity   -0.0314  -0.0711*** 
   -0.0081  (0.0123) 
Retinal Exam      
     Non PCMH 0.304*** 0.240*** 0.0645*** 0.333*** -0.029 
 (0.00285) (0.00371) (0.00466) (0.00625) (0.00675) 
     PCMH 0.281*** 0.224*** 0.0570*** 0.239*** 0.0417*** 
 (0.0132) (0.0108) (0.00835) (0.0157) (0.0136) 
     Δ Disparity   -0.00748  0.0707*** 
   (0.00716)  (0.0125) 
Attention for 
Nephropathy 
     
     Non PCMH 0.259*** 0.253*** 0.00649 0.340*** -0.0814 
 (0.00295) (0.00435) (0.00528) (0.00657) (0.00706) 
     PCMH 0.378*** 0.380*** -0.00143 0.426*** -0.0481 
 (0.0153) (0.0154) (0.00970) (0.0203) (0.0147) 
     Δ Disparity   -0.00791  0.0332*** 
   (0.00784)  (0.0127) 
Bootstrapped Standard Errors in Parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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CHAPTER 3: THE EFFECT OF LEVEL OF NCQA PATIENT-CENTERED 
MEDICAL HOME RECOGNITION ON RACIAL/ETHNIC DISPARITIES IN 
QUALITY OF CARE 
Overview 
Objective: Determine whether level of NCQA PCMH recognition is associated with 
improvements in overall quality of care and the reduction of racial/ethnic disparities in 
quality among patients with major depressive disorder (MDD) and comorbid chronic 
physical conditions. 
Data sources: Medicaid claims from 2008-2011 on beneficiaries age 18-64 years 
with MDD and at least one other chronic condition in Georgia, North Carolina, and Texas. 
Study design: We used generalized linear models to determine the probability of 
receiving eight disease-specific quality measures for MDD and diabetes. To measure 
disparities between racial groups (white, Black, and Hispanic/Latino), we used a rank-and-
replace method based on the Institute of Medicine definition of racial disparities that adjusts 
for health status and allows for mediation of socioeconomic factors. 
Data Collection: Medicaid claims merged with provider- and area-level data. 
Principal findings: We found that higher levels of NCQA recognition were associated 
with a reduction in the likelihood of receiving two quality measures. There was no 
statistically significant association between level of NCQA recognition and the remaining six 
measures. The effect of higher levels of NCQA recognition on racial/ethnic disparities on 
quality was mixed. 
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Conclusions: We found no evidence that higher level of NCQA recognition was 
associated with overall quality improvement for patients with MDD and comorbid chronic 
physical conditions. The effect of higher levels of NCQA recognition is inconsistent across 
racial groups, and sometimes, but not always associated with reductions in disparities. 
Background 
The patient-centered medical home (PCMH) model aims to improve outcomes, 
safety, system efficiency, and patient and provider experiences by reorganizing primary care 
into a team-based model that offers enhanced care coordination and disease management.1–3 
A growing body of evidence suggests that the PCMH is effective for chronic care and that 
PCMH transformation is associated with improved quality outcomes,4 especially for patients 
who require long-term management for chronic conditions, including behavioral health.5 For 
example, a 2012 study of PCMHs recognized by the National Committee on Quality 
Assurance (NCQA) found that PCMH enrollees were more likely than non-PCMH patients to 
receive A1c testing (82.11% vs. 77.7%), receive LDL screening (75.9% vs. 73.5%), and 
achieve LDL control (64.7% vs. 57.3%).6 
While the rationale for PCMH transformation is well-documented,2,7,8 patient 
populations may not benefit equally from this model, and the impact of the PCMH model on 
racial/ethnic disparities in quality has not been widely evaluated.2,9,10 Studies examining the 
effect of the PCMH on racial/ethnic disparities report mixed results.11 While some have 
found that the PCMH reduces or eliminates racial disparities in preventive care, cholesterol 
testing, and cancer screenings,12 others found an exacerbation of disparities in quality.13–17 
Given that minorities with behavioral health concerns are more likely to seek mental health 
services in primary care than from mental health specialists,18–21 it is important to assess 
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whether the PCMH has the potential to reduce disparities in quality of care among patients 
with MDD and chronic disease. 
One challenge to understanding the effect of PCMH on these patients is that its 
definition is inconsistent.11 Multiple organizations certify PCMH status, but the most the 
widely-used is the NCQA PCMH recognition program.22 Developed in 2008, NCQA offers 
three levels of recognition based on the number of PCMH elements adopted by a practice.4 
However, there is still considerable heterogeneity across PCMHs with the same level of 
NCQA recognition. This variability exists because the NCQA uses a flexible set of criteria to 
determine which recognition level a practice receives.23 Under the 2008 recognition criteria, 
there were nine standards and 100 possible points. Level 1 practices were required to achieve 
at least 25 points, level 2 recognition required 50 points, and level 3 recognition was awarded 
to practices that received 75 or more points. Yet even among PCMHs with the highest level 
of recognition, there are variations in the implementation of key medical home capabilities 
such as providing team-based care, providing referrals to community resources, and 
coordinating transitions of care.25 
Many existing Medicaid PCMH initiatives utilize incentive structures that base 
payments on NCQA recognition; over 50 payers offer enhanced reimbursement for NCQA-
recognized practices.26 Moreover, many PCMH demonstrations and initiatives utilize 
incentive structures that tie reimbursement to level of NCQA recognition.22,26 However, there 
is little evidence about how well quality outcomes correlate to NCQA level,22 and no 
evidence regarding the effect that NCQA PCMH recognition level has on racial/ethnic 
disparities in quality of care. We sought to determine whether level of NCQA PCMH 
recognition is associated with improvements in overall quality of care and the reduction of 
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racial/ethnic disparities for patients with MDD and comorbid physical conditions. We 
hypothesized that PCMHs with higher levels of NCQA accreditation would provide higher 
rates of guideline-concordant care overall and see greater reductions in racial/ethnic 
disparities compared to providers with lower recognition levels. 
Setting 
We used Medicaid claims from NCQA-recognized PCMHs during 2008-2011 in 
North Carolina, Georgia, and Texas. The NCQA’s PCMH recognition program was 
implemented in 2008; therefore, our study reflects the early stages of the program. During the 
study period, North Carolina was the only state in our sample with a state-developed medical 
home program.27 The state’s Medicaid PCMH program, Community Care of North Carolina 
(CCNC), began in 1998 as a primary care case management demonstration.28 While CCNC 
does not require participating providers to attain NCQA recognition, it offers resources and 
support for practices seeking recognition. During the study period, medical home initiatives 
in Georgia and Texas were largely supported by private partnerships.29,30 
Data 
We used a novel dataset constructed from several administrative data sources, 
including the Medicaid Analytic eXtract (MAX), the National Plan and Provider 
Enumeration System (NPPES), NCQA PCMH recognition data, the Area Health Resource 
File, and the U.S. Census Bureau’s Small Area Income and Poverty Estimates. The Medicaid 
MAX data files contain enrollment information and final claims for all enrolled Medicaid 
beneficiaries. We merged 2008-2011 MAX claims data from North Carolina, Georgia and 
Texas with NPPES data, which contains National Provider Identifiers (NPIs) and providers’ 
sex, provider type, state, and Medicaid billing identifiers. These data were merged with 
NCQA PCMH recognition data, which includes date, duration, and level of NCQA PCMH 
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recognition. Finally, county supply of mental health professionals was measured using data 
from the Area Health Resource File31 and county-level socioeconomic measures were 
derived from the U.S. Census Bureau’s Small Area Income and Poverty Estimates.32 
In addition to person-year outcomes, we also constructed an episode-level variable for 
minimally adequate antidepressant use because the guidelines for antidepressant use are 
based on episodes of treatment.41 For the episode-level measure, we focused on the acute 
phase guidelines because it is typically period of most intensive treatment.42 An acute 
episode was initiated by an outpatient service with a diagnosis of MDD or by initiation of 
antidepressant prescriptions, and we required two or more visits on different days and a 
period of at least three months without any new MDD claims before the initiation of a new 
episode. An episode was considered to have ended after either 120 days after the start of the 
episode or after 90 days of no MDD services or antidepressants. We adjusted for inpatient 
stays during these episodes by assuming beneficiaries received dispensed medication during 
an inpatient episode and resumed outpatient medications after discharge. 
Key Measures 
Dependent variables included four disease-specific quality indicators derived from 
Medicaid claims for MDD and an additional four measures for the subgroup with both MDD 
and diabetes (see Table 8 for full definitions). We conducted additional analyses in a 
subgroup of individuals with MDD and comorbid diabetes (Type I or Type II) because 
diabetes is a condition that is highly prevalent in Medicaid populations36,37 and because 
evidence indicates that comorbid MDD interferes with diabetes management.38 We selected 
quality measures based on recommended core quality measures for the PCMH,43 the Centers 
for Medicare and Medicaid Services (CMS) 2016 core set of adult quality measures for 
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Medicaid,44 and the 2011 version of the Healthcare Effectiveness Data and Information Set 
(HEDIS). 
Clinical guidelines for the treatment of MDD specify that treatment modality (i.e. use 
of antidepressants, psychotherapy, or both) should be based on clinical circumstances such as 
severity and complex psychosocial situations.45 Because this information is not available in 
administrative data, in person-year analyses we measured whether beneficiaries received any 
antidepressant prescriptions, at least one psychotherapy visit, or either. Either treatment 
modality would be considered guideline-concordant, therefore the receipt of any of these 
treatments are a minimum standard of quality.42,46 In episodic analyses, we assessed the 
HEDIS antidepressant management measure for effective acute phase treatment, defined as 
the likelihood that beneficiaries received at least 84 days of antidepressants during an acute 
episode.41 Finally, for the subgroup of beneficiaries with diabetes we measured the likelihood 
of receipt of A1c testing, lipids profiles, retinal exams, and attention for nephropathy using 
annual data. 
The exposure of interest was the level of NCQA-recognized PCMH to which a 
beneficiary was attributed. A provider’s NCQA PCMH status was determined annually using 
NCQA recognition data. If a provider changed levels in a calendar year, they were assigned 
the highest level of recognition during that year. We created a binary indicator of annual 
enrollment in an NCQA-certified PCMH using the CMS “plurality rule” commonly used for 
attributing beneficiaries to Accountable Care Organizations.47 A beneficiary’s primary care 
provider was defined as the provider that delivered the plurality of their non-hospital 
evaluation and management (NH-E&M) servies.48 In the event that a beneficiary received the 
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same number of services from two providers, they were attributed to the most recent 
provider.48 
Because this study is focused on a population with MDD, we modified the plurality 
rule to assign patients to the primary care providers that delivered most of their MDD care. 
We attributed beneficiaries to the primary care provider where they received the plurality of 
NH E&M claims with a primary diagnosis of MDD. If a beneficiary did not see a primary 
care provider for a MDD-related NH E&M claim in a year, they were then attributed to the 
primary care provider where they received the plurality of general NH E&M services. 
We derived beneficiary covariates from Medicaid claims, including age, sex, number 
of comorbidities (using the Agency for Healthcare Research and Quality’s Chronic Condition 
Indicator software49), number of Medicaid-enrolled months during the relevant time period 
(annual or episode), and rurality (urban, rural, or mixed indicators using simplified county-
level Rural-Urban Continuum Codes50). We derived beneficiary race data (white, Black, or 
Hispanic/Latino) from Medicaid claims; the remaining race categories were not sufficient for 
separate analysis, but these beneficiaries were included in the models for accuracy. For MDD 
and diabetes, we required that beneficiaries have at least one inpatient diagnosis or at least 
two outpatient or emergency department diagnoses during a single year in the study period, 
and at least one claim for the condition in each year to avoid “rule-out” diagnoses and/or 
errors in coding. PCMH-level covariates were derived from NPPES and NCQA recognition 
data and included Federally Qualified Health Center or Rural Health Center status, provider 
sex, and level of NCQA attribution. County-level socioeconomic characteristics were 
measured using percent of the population under poverty and median income. County-level 
supply of mental health professionals were included to control for the availability of 
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providers, which may be correlated with PCMH measures, and was measured using county 
supply of psychiatrists and Mental Health Professional Shortage Area (HPSA) status. 
The Institute of Medicine (IOM) defines a racial disparity in health care as “racial or 
ethnic differences in the quality of health care that are not due to access-related factors or 
clinical needs, preferences, and appropriateness of intervention.’’51 Under this definition, 
measuring a disparity requires distinguishing differences driven by underlying health status 
or preference from those that are driven by healthcare systems factors or discrimination.51,52 
Unlike predictive margins, which estimate residual direct effect, or the unmediated effect of 
race/ethnicity after adjusting for all measured covariates, this definition accounts for the 
effects of mediating factors (other than health status and preferences), such as variables 
associated with geography or socioeconomic status.51,53 We estimated racial disparities using 
the following IOM-compliant process: 1) fit a model describing relationships between 
quality/utilization and health status, race, and other characteristics using non-Hispanic whites 
as a reference group 2) transform the distributions of health status variables (age, gender, and 
number of comorbidities) for minority groups to be the same as those of non-Hispanic whites 
using a rank and replace method while leaving other variables unchanged 3) calculate 
predictions using the coefficients from the initial models and the transformed health status 
distributions for minority groups, and 4) aggregate these predictions by racial group to 
estimate disparities.52 We generated standard errors for these aggregated predictions using 
500 bootstrap iterations. 
Statistical Analysis 
The study population included non-elderly adult Medicaid beneficiaries with major 
depressive disorder (MDD) and at least one other physical chronic condition who are not 
dually enrolled in Medicare. We selected this population because adults with MDD and other 
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comorbid chronic conditions typically receive lower quality care33,34 and because Medicaid 
beneficiaries have disproportionately high rates of comorbid behavioral and physical health 
conditions.35 The sample was restricted to individuals contributing at least partial years of 
Medicaid enrollment during the study period (2008-2011). Individuals with schizophrenia or 
bipolar disorder were excluded because specialty providers are more likely to serve as the 
primary point of contact with the healthcare system for this population.40 The sample was 
limited to years in which beneficiaries received care from a provider that achieved PCMH 
recognition at any point during the study period, including years prior to recognition. 
Because receipt of care in a PCMH is non-random, PCMH status may be endogenous. 
To determine whether bias due to differential selection into varying levels of NCQA-
recognized PCMHs was a concern, we ran a two-stage residual inclusion (2SRI) model 
where the first stage was an ordered logit on recognition levels 1-3. The second stage 
included two predicted residuals from the first stage equation; one residual was excluded 
because of collinearity. Equation 1 shows the second stage model, which includes the 
predicted residuals for levels 1 and 3: 
Equation 1: Yit= β0 + β1*PCMH_enrollmentit + β2*Xipct + β3*predicted_residuals + εipct 
where Y represents a set of dependent variables, defined as the receipt of each quality 
indicator. We found no evidence of selection bias; a Hausman test determined that the results 
were not significantly different with and without this instrumental variable approach. 
Therefore, we assessed the effect of level of NCQA PCMH recognition on the 
likelihood of receiving each quality measure using generalized linear models (GLM) with a 
binomial family and logit link. The referent group for the overall quality models was 
practices that had not yet achieved NCQA recognition. For disparities models, the referent 
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group was practices with level 1 NCQA recognition. During the model selection process, we 
also assessed generalized estimating equations (GEE) with three different correlation 
structures to account for clustering across repeated observations: independent, exchangeable, 
and unstructured. The quasi-likelihood under the independence model criterion (QIC) 
indicated that the independent correlation structure was the best fit for the data. This is likely 
because 79% of beneficiaries contributed only one year of data. Beneficiaries attributed to 
years prior to a provider achieving recognition were included as the referent group (pre-
recognition years). We included state and year fixed effects to account for time-invariant 
confounders due to geographic differences and time trends. In addition, we conducted 
sensitivity analyses including practice-level fixed effects. The results of these models were 
almost identical to the primary analyses in magnitude, direction, and significance. We used 
the likelihood ratio test to assess the functional form of covariates, including quadratic forms 
of age and median income and interactions between race, median income, and percent under 
poverty. The results indicated that age should be included as a quadratic, but other higher-
order and interaction terms did not improve model fit. The equation for the GLM was: 
Equation 2: Yit= β0 + β1*NCQA_levelpt + β2*Xipct + µpt + µs + εipct 
where NCQA_ level represents level of NCQA PCMH accreditation, i, p, and c 
represent individual, provider, and county level variables and t is the time-period (year). 
Finally, µs and µpt represent fixed effects at the state and year level. Marginal effects for the 
overall estimates were obtained using predictive margins and Delta method standard errors. 
In the disparities models, predicted probabilities were obtained using the methods described 
above and standard errors were obtained via bootstrapping (500 replicates). Bootstrap 
replicates were clustered at the beneficiary level to account for repeated observations over 
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time. All analyses were performed using Stata (Version 13). We also conducted sensitivity 
analyses using a different definition of PCMH attribution; in these analyses PCMH 
enrollment was defined as any claim with an NCQA-recognized PCMH provider during a 
year. We retained observations from patients attributed to an NCQA-recognized PCMH 
practice both prior to recognition as well as during recognition periods, to estimate the effect 
that recognition level had on quality outcomes. 
Results 
The final sample (Table 9) consisted of 9,169 person-years contributed by 7,343 
unique beneficiaries, and a total of 262 NCQA-PCMH recognized providers. The sample 
included data on pre-recognition years for 228 providers. The majority (40.2%) of 
beneficiary-years were attributed to a level 3 NCQA PCMH. 8.3% of beneficiary-years were 
attributed to level 1 PCMHs and 4.6% were attributed to a level 2 PCMH. The remaining 
beneficiary-years were attributed to pre-recognition practices. The average beneficiary age 
was 40. The overall sample was 53.3% white, 35.3% Black, and 8.1% Hispanic/Latino. 
In unadjusted comparisons (Table 10), bivariate tests of differences in service use 
were all statistically significant. Level 3 enrollees had the highest rates of any annual 
antidepressant use (73.0%), episodic antidepressant use (32.7%), and A1c testing (79.9%). 
Because of higher rates of antidepressant use, level 3 enrollees also had the highest rates of 
receipt of either psychotherapy or antidepressants (84.0%). Level 2 enrollees had the highest 
rates of receipt of psychotherapy (38.7%). Level 1 enrollees had the highest rates of attention 
for nephropathy (47.5%). Finally, beneficiaries in pre-recognition years had the highest rates 
of retinal exams (36.4%) and lipids panels (69.7%). 
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Overall Quality 
We found that compared to the pre-recognition period, PCMH enrollees in level 1 
medical homes saw a 5.90 percentage point decrease in the likelihood of any yearly 
antidepressant use (p<0.01) and level 2 enrollees saw a decrease of 7.34 percentage points 
(p<0.01) (Table 11). There was no statistically significant association between level 3 
enrollment and annual receipt of antidepressants. Level 2 enrollees also had a 16.5 
percentage point decrease in receipt of lipids panels (p<0.01), but there was no statistically 
significant association for enrollees in levels 1 or 3. We found no statistically significant 
association between level of PCMH enrollment and yearly receipt of psychotherapy. In 
episodic analyses, we also found no statistically significant association between NCQA 
recognition level and minimally adequate antidepressant use. Finally, in diabetes models, 
(Table 12), we found no statistically significant association between level of NCQA 
recognition and A1c testing, retinal exams, or attention for nephropathy. 
In fully-adjusted models that control for socioeconomic and geographic factors, Black 
enrollees overall were 7.80 percentage points more likely to receive psychotherapy than their 
white counterparts (p<0.01). Black enrollees were also less likely to receive annual 
antidepressants (-13.6 percentage points, p<0.01), minimally adequate antidepressants (-15.4 
percentage points, p<0.01), either psychotherapy or antidepressants (-5.18 percentage points, 
p<0.01), lipids panels (4.67 percentage points, p<0.01). Hispanic/Latino enrollees were 6.82 
percentage points more likely to receive yearly psychotherapy (p<0.01) and 4.35 percentage 
points less likely to receive to receive yearly antidepressants (p<0.05). 
In sensitivity analyses defining PCMH enrollment as any claims with an NCQA 
recognized provider during a given year, the results were consistent with the primary 
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analyses in direction and magnitude. However, we found no statistically significant 
associations between level of NCQA recognition and the eight quality measures assessed. 
Racial Disparities 
We found that both Black and Hispanic/Latino enrollees had higher rates of receipt of 
annual psychotherapy than whites, and these disparities persisted in all three levels of NCQA 
recognition (Table 13). In annual antidepressant use, we found statistically significant 
disparities for both Black and Hispanic/Latino beneficiaries in all three levels of recognition. 
Compared to their counterparts enrolled in a level 1 PCMH, Black enrollees in level 3 saw a 
4.20 percentage point reduction in disparities (p<0.05). Disparities in this measure were also 
reduced by 27.5 percentage points for Hispanic/Latino beneficiaries enrolled in level 3, as 
compared to their counterparts in level 1 and by 19.3 percentage points relative to enrollees 
in level 2. In receipt of either annual MDD measure, Black beneficiaries enrolled in a level 2 
or 3 PCMH saw a statistically significant decrease over Black beneficiaries enrolled in level 
1. Finally, while Hispanic/Latino beneficiaries in level 3 PCMHs saw a 5.83 percentage point 
reduction in disparities for minimally adequate episodic antidepressant use versus level 1 
(p<0.05) and a 5.18 percentage point reduction versus level 2 (p<0.1), Black beneficiaries in 
a level 3 PCMH saw a 4.02 percentage point exacerbation in disparities for this measure 
(p<0.05). 
For diabetes (Table 14), we found statistically significant Black-white and Hispanic-
white disparities in receipt of lipids panels at all three NCQA PCMH levels. Although both 
groups improved in level 3, these disparities were exacerbated for Black beneficiaries in a 
level 3 PCMH; we found a Black-white disparity in receipt of lipids panels of -25.9 
percentage points among level 3 enrollees, compared to -16.4 percentage points among 
enrollees in level 2 and 15.0 percentage points among level 1 enrollees (p’s<0.01). There was 
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no statistically significant reduction in Hispanic-white disparities for receipt of lipids panels. 
A statistically significant Black-white disparity existed in the level 3 group for receipt of A1c 
testing, but not for the level 1 or level 2 groups, suggesting that disparities were exacerbated 
among level 3 enrollees, even though both Black and white beneficiaries saw higher 
predicted probabilities for A1c in level 3 than in levels 1 and 2. We saw a similar pattern in 
Hispanic-white disparities in retinal exams and attention for nephropathy. For retinal exams 
there was a Hispanic-white disparity of 6.84 percentage points among level 3 enrollees but 
no statistically significant disparity among level 1 or 2 enrollees. For attention for 
nephropathy, the Hispanic-white disparity among level 3 enrollees was 7.28 percentage 
points (p<0.1), and there were no statistically significant disparities among enrollees in levels 
1 or 2. We saw no statistically significant Black-white disparities in any PCMH level for 
either of these measures. 
Discussion 
Contrary to our hypothesis, we did not find any statistically significant improvements 
in overall quality among Medicaid beneficiaries with higher levels of NCQA PCMH 
recognition. In fact, we found that enrollees in levels 2 and 3 were less likely to receive any 
annual antidepressants and lipids panels, compared to beneficiaries enrolled in practices that 
have not yet received recognition. 
In IOM-compliant disparities analyses, we found statistically significant disparities 
between racial groups for several measures. We found that while both Black and white 
enrollees in a level 3 PCMH saw an increase in A1c testing compared to levels 1 and 2, white 
enrollees saw a larger improvement, exacerbating disparities between these groups. 
Conversely, disparities analyses suggest that higher levels of NCQA recognition are 
associated with reductions in Black-white and Hispanic-white disparities in yearly receipt of 
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antidepressants. Notably, our analyses focus on Medicaid beneficiaries and therefore these 
results are not driven by insurance status. While prior research has shown that racial 
disparities in care are often driven in large part by differential access to insurance coverage,54 
our results suggest that disparities in some quality measures persist even among individuals 
with comparable insurance coverage.  
In the fully-adjusted models, null results may be because the comparison was 
composed of group practices that had not yet attained NCQA recognition, and these practices 
may already have been high-performers. Therefore, achieving NCQA recognition did not 
improve outcomes. The overall lack of association between level of NCQA recognition and 
quality outcomes may also be due to heterogeneity of practice characteristics, even within the 
same level of recognition. A 2014 study found that even among practices with the same level 
of certification, different types of practices demonstrated strengths in different PCMH 
capabilities. For example, among practices with NCQA PCMH recognition, community 
health centers were significantly more likely to have scored full credit for after-hours access 
while more large physician-owned practices received full credit for having structured data on 
patient demographics and clinical data.25 Similarly, prior work has shown that affiliation 
larger practices health systems provided PCMHs with more support for implementing the 
core activities of the medical home, including population management, care coordination, 
and quality measurement/improvement.4 Finally, “intangible” or difficult-to-measure 
contextual factors such as engaged leadership are important indicators of high-performing 
primary care practices, but these factors are not easily reflected in the NCQA recognition 
criteria.55,56 
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Limitations 
This study has several limitations. First, PCMH recognition level may be achieved 
through different combinations of activities, and there is likely great heterogeneity of 
available services or practice characteristics within recognition levels. However, these 
recognition categories are relevant in a “real-world” setting that incentivize NCQA-
recognition levels. Second, the measures used in this study are utilization-based quality 
indicators; other practice-based measures of quality may show different results. Third, 
because individual-level socioeconomic data are not available in Medicaid claims, we used 
county-level measures of socioeconomic status. Previous studies have shown that using area-
based socioeconomic measures is a reasonable method to address the absence of 
socioeconomic data in claims.57 Third, we only have claims data for services paid by 
Medicaid. This should not cause bias as this underreporting would not differentially affect 
enrollees in different levels of NCQA PCMH. Fourth, although NCQA is the most prevalent 
PCMH recognition program,22 our results may not be generalizable to PCMHs recognized by 
accrediting body. Finally, measures of patient perspective or experience of care are not 
available in administrative claims data. 
Conclusions 
Our findings show that higher levels of NCQA recognition are not directly associated 
with improvements in quality outcomes. However, the effects of PCMH recognition vary 
across racial groups. Enrollment in a higher level of NCQA is sometimes, but not always 
associated with a reduction in racial/ethnic disparities in quality of care, and for some metrics 
disparities were exacerbated for beneficiaries enrolled in a PCMH with the highest level of 
NCQA recognition. This suggests that while incentivizing practices to attain higher levels of 
NCQA recognition has potential to reduce disparities, higher levels of NCQA recognition 
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alone may not be sufficient to reduce racial inequities in quality of care. Providers or 
policymakers should consider racial/ethnic disparities explicitly when designing, 
implementing, and evaluating PCMH programs. 
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Table 8: Disease-Specific Dependent Variables 
Variable Definition 
Calendar-
Year 
Acute 
Episode 
MDD 
Antidepressant 
use 
Percent of patients with MDD who received any 
antidepressant prescriptions. 
X  
At least 84 days of antidepressants during a 120-day 
episode. 
 X 
Psychotherapy 
Percent of patients with MDD receiving any 
group/individual psychotherapy  
X  
Any MDD 
treatment 
Receipt of any antidepressant prescriptions or 
group/individual psychotherapy  
X  
Diabetes 
A1C Testing Percent of diabetic patients receiving A1C testing  X  
LDL-C 
Testing 
Percent of diabetic patients receiving an LDL–C test  X  
Retinal exam Percent of diabetic patients receiving a retinal exam  X  
Nephropathy 
screening 
Percent of diabetic patients screened for nephropathy  X  
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Table 9: Summary Statistics (Person-Years) 
 N(%) or Mean(SD) 
Factor Total 
Pre-
Recognition Level 1 Level 2 Level 3 
N 9,169 4,303 (46.9%) 762 (8.3%) 421 (4.6%) 3683 (40.2%) 
Female Beneficiary 7,299 (79.6%) 3,370 (78.3%) 587 (77.0%) 308 (73.2%) 3034 (82.4%) 
Beneficiary Age 40.73 (13.42) 41.39 (13.47) 43.37 (13.18) 43.54 (13.05) 39.10 (13.25) 
Race      
White 4,888 (53.3%) 2,380 (55.3%) 365 (47.9%) 159 (37.8%) 1,984 (53.9%) 
Black 3,241 (35.3%) 1,338 (31.1%) 280 (36.7%) 225 (53.4%) 1,398 (38.0%) 
Hispanic/Latino 534 (5.8%) 348 (8.1%) 43 (5.6%) 22 (5.2%) 121 (3.3%) 
Months of 
Medicaid 
Enrollment 10.72 (2.41) 10.63 (2.51) 10.73 (2.41) 10.74 (2.53) 10.82 (2.27) 
# Chronic 
Conditions 5.35 (4.20) 5.38 (4.13) 5.85 (4.78) 4.96 (3.76) 5.25 (4.17) 
Female Provider 3,515 (38.3%) 1,469 (34.1%) 272 (35.7%) 162 (38.5%) 1,612 (43.8%) 
FQHC 283 (3.1%) 116 (2.7%) 73 (9.6%) 0 (0.0%) 94 (2.6%) 
RHC 95 (1.0%) 23 (0.5%) 0 (0.0%) 0 (0.0%) 72 (2.0%) 
County % Under 
Poverty 17.67 (3.64) 17.11 (3.57) 19.05 (4.13) 17.71 (1.49) 18.03 (3.67) 
County Median 
Income 
45,223.93 
(6752.08) 
45,204.65 
(6925.6125) 
44,800.913 
(7345.1623) 
44,846.964 
(2856.3185) 
45,377.036 
(6732.24) 
Rural      
Metropolitan 8196 (89.4%) 3785 (88.1%) 670 (87.9%) 414 (98.3%) 3327 (90.3%) 
Metro-Adjacent 819 (8.9%) 435 (10.1%) 59 (7.7%) 7 (1.7%) 318 (8.6%) 
Rural 148 (1.6%) 77 (1.8%) 33 (4.3%) 0 (0.0%) 38 (1.0%) 
HPSA      
Full  1601 (17.5%) 1047 (24.4%) 300 (39.4%) 41 (9.7%) 213 (5.8%) 
Partial 4767 (52.0%) 2208 (51.4%) 270 (35.4%) 11 (2.6%) 2278 (61.9%) 
State      
GA 530 (5.8%) 233 (5.4%) 141 (18.5%) 0 (0.0%) 156 (4.2%) 
NC 7245 (79.0%) 3042 (70.7%) 427 (56.0%) 382 (90.7%) 3394 (92.2%) 
TX 1394 (15.2%) 1028 (23.9%) 194 (25.5%) 39 (9.3%) 133 (3.6%) 
Year      
2008 777 (8.5%) 777 (18.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
2009 1,711 (18.7%) 1,621 (37.7%) 66 (8.7%) 11 (2.6%) 13 (0.4%) 
2010 3,552 (38.7%) 1,905 (44.3%) 344 (45.1%) 191 (45.4%) 1,112 (30.2%) 
2011 3,129 (34.1%) 0 (0.0%) 352 (46.2%) 219 (52.0%) 2,558 (69.5%) 
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Table 10: Unadjusted Rates of Quality Metrics 
 
Pre-
Recognition 
Level 1 Level 2 Level 3 P value (χ2) 
MDD 
Calendar Year      
   Any psychotherapy 1,390 (32.3%) 270 (35.4%) 163 (38.7%) 1,313 (35.7%) 0.002 
   Any antidepressants 3,001 (69.7%) 456 (59.8%) 264 (62.7%) 2,687 (73.0%) <0.001 
Any MDD treatment 3,407 (79.2%) 553 (72.6%) 326 (77.4%) 3,092 (84.0%) <0.001 
   N 4,303 762 421 3,683  
Acute Episode      
   Min. antidepressants 886 (27.4%) 138 (24.2%) 78 (26.0%) 876 (32.7%) <0.001 
   N 3,236 571 300 2,675  
Diabetes 
   A1c testing 927 (79.2%) 169 (69.0%) 76 (69.1%) 673 (79.9%) <0.001 
   Retinal exam 426 (36.4%) 70 (28.6%) 37 (33.6%) 239 (28.4%) <0.001 
   Lipids panel 815 (69.7%) 135 (55.3%) 55 (50.0%) 561 (66.6%) <0.001 
   Attn for nephropathy 491 (42.0%) 116 (47.5%) 31 (28.2%) 342 (40.6%) 0.007 
   N 1,170 245 110 842  
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Table 11: Average Marginal Effects of NCQA PCMH on MDD Outcomes 
 
Any 
Psychotherapy 
Any 
Antidepressants 
Any MDD 
Treatment 
Adequate 
Antidepressants 
NCQA Level 1 0.0301 -0.0590*** -0.0224 -0.0350 
 (0.0234) (0.0209) (0.0170) (0.0234) 
NCQA Level 2 0.0409 -0.0734*** -0.0219 -0.0407 
 (0.0300) (0.0276) (0.0232) (0.0293) 
NCQA Level 3 -0.0190 -0.000118 0.0101 -0.00623 
 (0.0176) (0.0158) (0.0134) (0.0177) 
Race     
Black 0.0780*** -0.136*** -0.0518*** -0.154*** 
 (0.0127) (0.0116) (0.00974) (0.0123) 
Hispanic/Latino 0.0682*** -0.0435** 0.00482 -0.0375 
 (0.0255) (0.0208) (0.0152) (0.0288) 
# Chronic Conditions -0.00210 0.0104*** 0.00192* 0.00807*** 
 (0.00148) (0.00139) (0.00111) (0.00153) 
Rurality     
Metro-adjacent 0.0477** 0.000468 0.0221 0.0181 
 (0.0219) (0.0200) (0.0158) (0.0217) 
Rural 0.107** 0.00398 0.0126 0.0136 
 (0.0483) (0.0433) (0.0347) (0.0465) 
Beneficiary Age -0.00286*** 0.000324 -0.00134*** 0.00190*** 
 (0.000452) (0.000429) (0.000359) (0.000456) 
Female Beneficiary -0.0138 0.0745*** 0.0399*** 0.0125 
 (0.0134) (0.0123) (0.0102) (0.0136) 
# Months Medicaid 
Enrollment 0.0121*** 0.0177*** 0.0158*** 0.00877*** 
 (0.00229) (0.00184) (0.00144) (0.00245) 
FQHC -0.0883*** 0.0754*** 0.0197 0.0347 
 (0.0304) (0.0279) (0.0257) (0.0345) 
RHC -0.245*** 0.0899* 0.00283 0.0610 
 (0.0385) (0.0483) (0.0446) (0.0491) 
Female Provider 0.00320 0.0120 0.0215** 0.0100 
 (0.0114) (0.0100) (0.00838) (0.0117) 
County % Under 
Poverty 0.0169*** -0.0160*** -0.00423** -0.0117*** 
 (0.00261) (0.00232) (0.00188) (0.00278) 
County Median 
Income 3.77e-06** -7.68e-06*** -2.13e-06** -3.32e-06** 
 (1.55e-06) (1.33e-06) (1.06e-06) (1.57e-06) 
Count # Psychiatrists  0.000350*** 0.000160** 0.000133** -2.50e-05 
 (9.99e-05) (7.83e-05) (5.89e-05) (0.000110) 
Mental Health 
HPSA     
Full 0.0244 -0.00429 -0.0119 -0.0309 
 (0.0233) (0.0203) (0.0169) (0.0230) 
Partial 0.0336** -0.00653 -0.000921 -0.0177 
 (0.0131) (0.0120) (0.0103) (0.0130) 
Year     
2009 -0.0277 0.0157 0.0231 0.0932*** 
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Any 
Psychotherapy 
Any 
Antidepressants 
Any MDD 
Treatment 
Adequate 
Antidepressants 
 (0.0230) (0.0206) (0.0162) (0.0243) 
2010 -0.0632*** 0.0414** 0.0175 0.0791*** 
 (0.0230) (0.0209) (0.0167) (0.0238) 
2011 -0.0343 0.0273 0.0134 0.141*** 
 (0.0282) (0.0255) (0.0209) (0.0286) 
State (Referent: 
Georgia)     
North Carolina 0.217*** 0.0963*** 0.130*** 0.0681*** 
 (0.0211) (0.0245) (0.0230) (0.0259) 
Texas 0.0439 -0.128*** -0.0650** -0.0705** 
 (0.0281) (0.0333) (0.0320) (0.0308) 
Delta Method standard errors in parentheses *** p<0.01, ** p<0.05, * p<0.1 
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Table 12: Average Marginal Effects of NCQA PCMH on Diabetes Outcomes 
 Lipids Panel A1c Retinal Exam Attention for Nephropathy 
          
NCQA Level 1 -0.0226 -0.0539 -0.0373 0.0576 
 (0.0387) (0.0365) (0.0373) (0.0419) 
NCQA Level 2 -0.165*** -0.0814 0.0420 -0.0843 
 (0.0552) (0.0512) (0.0541) (0.0558) 
NCQA Level 3 -0.0118 -0.00232 -0.0153 -0.0274 
 (0.0312) (0.0285) (0.0301) (0.0331) 
Race     
Black -0.0467** 0.0129 0.00671 0.00293 
 (0.0219) (0.0198) (0.0221) (0.0238) 
Hispanic/Latino -0.0330 0.0412 0.0505 -0.0383 
 (0.0394) (0.0327) (0.0400) (0.0411) 
# Chronic 
Conditions 0.00508** 0.00748*** 0.0159*** 0.00793*** 
 (0.00213) (0.00199) (0.00195) (0.00219) 
Rurality     
Metro-adjacent  0.0731** 0.0517* 0.0573 0.0508 
 (0.0351) (0.0305) (0.0394) (0.0412) 
 Rural 0.00676 -0.0181 -0.153** 0.0273 
 (0.0810) (0.0773) (0.0630) (0.0881) 
Beneficiary 
Age -0.000758 -0.00147 -0.000270 -0.00311*** 
 (0.00111) (0.00101) (0.00110) (0.00114) 
Female 
Beneficiary 0.000340 -0.0207 0.0321 -0.0416* 
 (0.0225) (0.0197) (0.0223) (0.0243) 
# Months 
Medicaid 
Enrollment 0.0313*** 0.0200*** 0.0129*** 0.0182*** 
 (0.00387) (0.00332) (0.00465) (0.00482) 
FQHC -0.114* -0.0275 -0.0585 0.00815 
 (0.0624) (0.0561) (0.0574) (0.0645) 
RHC -0.0180 -0.0235 0.158 -0.136 
 (0.106) (0.101) (0.113) (0.0986) 
Female 
Provider 0.000131 0.0359** 0.0174 0.0672*** 
 (0.0202) (0.0178) (0.0204) (0.0219) 
County % 
Under Poverty 0.00665 -0.00279 0.00731* -0.00985** 
 (0.00446) (0.00393) (0.00437) (0.00474) 
County Median 
Income 3.68e-06 -1.45e-06 1.40e-06 -3.07e-06 
 (2.70e-06) (2.39e-06) (2.72e-06) (2.89e-06) 
County # 
Psychiatrists  1.84e-06 -7.80e-05 -0.000163 -0.000216 
 (0.000158) (0.000137) (0.000151) (0.000166) 
Mental Health 
HPSA     
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 Lipids Panel A1c Retinal Exam Attention for Nephropathy 
          
Full -0.0501 0.000494 -0.0289 0.0774* 
 (0.0409) (0.0366) (0.0393) (0.0424) 
Partial -0.00887 0.0270 -0.0105 0.0943*** 
 (0.0240) (0.0222) (0.0247) (0.0256) 
Year     
2009 0.0174 0.0505 0.0235 0.0258 
 (0.0366) (0.0350) (0.0375) (0.0389) 
2010 0.00232 0.0827** 0.0859** 0.0711* 
 (0.0370) (0.0363) (0.0372) (0.0386) 
2011 -0.0769 0.0210 -0.0773* 0.0644 
 (0.0475) (0.0465) (0.0438) (0.0489) 
 
State 
(Referent: 
Georgia)     
North Carolina 0.356*** 0.152*** 0.0160 0.00993 
 (0.0404) (0.0424) (0.0382) (0.0421) 
Texas 0.371*** 0.153*** 0.115** 0.0886* 
 (0.0502) (0.0497) (0.0497) (0.0530) 
Delta Method standard errors in parentheses   *** p<0.01, ** p<0.05, * p<0.1 
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Table 13: Comparison of Predicted Probabilities and Disparities Changes for MDD 
Outcomes 
 White Black Disparity Hispanic/Latino Disparity 
Psychotherapy     
   Level 1 0.346*** 0.493*** -0.146*** 0.514*** -0.168*** 
 (0.0209) (0.0261) (0.0206) (0.0452) (0.0422) 
   Level 2 0.383*** 0.537*** -0.154*** 0.511*** -0.128*** 
 (0.0291) (0.0322) (0.0251) (0.0455) (0.0400) 
   Level 3 0.337*** 0.497*** -0.160*** 0.453*** -0.116*** 
 (0.0100) (0.0154) (0.0169) (0.0289) (0.0290) 
Δ Disparity 
     
   2 vs 1 
  
-0.00783 
 
0.0405 
 
  
(0.0188) 
 
(0.0354) 
   3 vs 1 
  
-0.0131 
 
0.0522 
 
  
(0.0146) 
 
(0.0382) 
   3 vs 2  
  
-0.00531 
 
0.0116 
 
  
(0.0158) 
 
(0.0334) 
Any Antidepressants 
   
   Level 1 0.728*** 0.452*** 0.275*** 0.332*** 0.396*** 
 (0.0199) (0.0235) (0.0206) (0.0489) (0.0494) 
   Level 2 0.754*** 0.490*** 0.264*** 0.441*** 0.313*** 
 (0.0235) (0.0314) (0.0247) (0.0667) (0.0656) 
   Level 3 0.820*** 0.587*** 0.233*** 0.700*** 0.121*** 
 (0.00782) (0.0147) (0.0144) (0.0275) (0.0270) 
Δ Disparity 
     
   2 vs 1 
  
-0.0108 
 
0.0822 
 
  
(0.0249) 
 
(0.0728) 
   3 vs 1 
  
-0.0420** 
 
0.275*** 
 
  
(0.0181) 
 
(0.0468) 
   3 vs 2  
  
0.0313 
 
0.193*** 
 
  
(0.0198) 
 
(0.0610) 
Either 
     
   Level 1 0.812*** 0.714*** 0.0973*** 0.686*** 0.125*** 
 (0.0178) (0.0244) (0.0216) (0.0472) (0.0461) 
   Level 2 0.856*** 0.800*** 0.0564** 0.740*** 0.116** 
 (0.0189) (0.0283) (0.0220) (0.0503) (0.0479) 
   Level 3 0.891*** 0.839*** 0.0519*** 0.874*** 0.0174 
 (0.00632) (0.0122) (0.0120) (0.0175) (0.0172) 
Δ Disparity 
     
   2 vs 1 
  
-0.0410** 
 
-0.00960 
 
  
(0.0179) 
 
(0.0446) 
   3 vs 1 
  
-0.0454*** 
 
-0.108*** 
 
  
(0.0149) 
 
(0.0402) 
   3 vs 2  
  
-0.00442 
 
-0.0984** 
 
  
(0.0143) 
 
(0.0434) 
Adequate Antidepressants     
Level 1 0.309*** 0.112*** 0.197*** 0.113*** 0.195***  
(0.0238) (0.0127) (0.0173) (0.0198) (0.0234) 
   Level 2 0.344*** 0.165*** 0.180*** 0.155*** 0.189*** 
  (0.0332) (0.0204) (0.0212) (0.0331) (0.0342) 
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 White Black Disparity Hispanic/Latino Disparity 
   Level 3 0.397*** 0.178*** 0.220*** 0.260*** 0.137*** 
 (0.0120) (0.00989) (0.0132) (0.0307) (0.0300) 
Δ Disparity 
     
   2 vs 1 
  
-0.0170 
 
-0.00642 
 
  
(0.0230) 
 
(0.0321) 
   3 vs 1 
  
0.0232 
 
-0.0583** 
 
  
(0.0168) 
 
(0.0250) 
   3 vs 2  
  
0.0402** 
 
-0.0518* 
 
  
(0.0176) 
 
(0.0288) 
Bootstrapped Standard Errors in Parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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Table 14: Comparison of Predicted Probabilities and Disparities Changes for Diabetes 
Outcomes 
 
White Black Disparity 
Hispanic/ 
Latino Disparity 
Lipids      
   Level 1 0.544*** 0.394*** 0.150*** 0.284*** 0.260*** 
 (0.0396) (0.0488) (0.0505) (0.0794) (0.0796) 
   Level 2 0.502*** 0.338*** 0.164*** 0.273* 0.229* 
 (0.0611) (0.0492) (0.0533) (0.140) (0.137) 
   Level 3 0.699*** 0.440*** 0.259*** 0.553*** 0.146** 
 (0.0221) (0.0409) (0.0434) (0.0568) (0.0573) 
Δ Disparity      
   2 vs 1   0.0141  -0.0306 
   (0.0588)  (0.140) 
   3 vs 1   0.109**  -0.113 
   (0.0455)  (0.0720) 
   3 vs 2    0.0951**  -0.0826 
   (0.0480)  (0.139) 
A1c      
   Level 1 0.661*** 0.580*** 0.0808 0.533*** 0.128 
 (0.0393) (0.0699) (0.0655) (0.122) (0.118) 
   Level 2 0.644*** 0.582*** 0.0625 0.515*** 0.129 
 (0.0540) (0.0819) (0.0735) (0.154) (0.144) 
   Level 3 0.799*** 0.672*** 0.127* 0.754*** 0.0450 
 (0.0188) (0.0665) (0.0683) (0.0466) (0.0471) 
Δ Disparity      
   2 vs 1   -0.0183  0.00179 
   (0.0479)  (0.113) 
   3 vs 1   0.0465  -0.0827 
   (0.0337)  (0.0959) 
   3 vs 2    0.0648*  -0.0845 
   (0.0393)  (0.129) 
Retinal Exam      
   Level 1 0.268*** 0.250*** 0.0174 0.301*** -0.0329 
 (0.0304) (0.0510) (0.0487) (0.0968) (0.0954) 
   Level 2 0.295*** 0.312*** -0.0165 0.444*** -0.148 
 (0.0462) (0.0689) (0.0550) (0.121) (0.108) 
   Level 3 0.284*** 0.244*** 0.0395 0.216*** 0.0684* 
 (0.0188) (0.0438) (0.0442) (0.0385) (0.0383) 
Δ Disparity      
   2 vs 1   0.0340  -0.115 
   (0.0350)  (0.0739) 
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White Black Disparity 
Hispanic/ 
Latino Disparity 
   3 vs 1   0.0221  0.101 
   (0.0245)  (0.0805) 
   3 vs 2    0.0561*  0.217** 
   (0.0300)  (0.0936) 
Attention for 
Nephropathy 
     
   Level 1 0.470*** 0.428*** 0.0426 0.351*** 0.120 
 (0.0369) (0.0622) (0.0584) (0.100) (0.0979) 
   Level 2 0.261*** 0.243*** 0.0177 0.212** 0.0488 
 (0.0472) (0.0609) (0.0488) (0.0918) (0.0832) 
   Level 3 0.414*** 0.345*** 0.0694 0.341*** 0.0728* 
 (0.0211) (0.0535) (0.0537) (0.0446) (0.0438) 
Δ Disparity      
   2 vs 1   -0.0249  -0.0708 
   (0.0316)  (0.0670) 
   3 vs 1   0.0268  -0.0468 
   (0.0245)  (0.0835) 
   3 vs 2    0.0517**  0.0240 
   (0.0260)  (0.0758) 
Bootstrapped Standard Errors in Parentheses 
*** p<0.01, ** p<0.05, * p<0.1 
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CHAPTER 4: HETEROGENEITY OF TREATMENT EFFECTS IN PATIENT-
CENTERED MEDICAL HOMES: ADULTS WITH DEPRESSION AND MULTIPLE 
CHRONIC CONDITIONS 
Overview 
Objective: Identify the subgroups of adults with major depressive disorder (MDD) 
and other chronic conditions most likely to benefit from participation in a patient-centered 
medical home PCMH). 
Data sources: Administrative claims from 2008-2011 on Medicaid beneficiaries age 
18-64 years with MDD and at least one other chronic condition in Georgia, North Carolina, 
and Texas. 
Study design: We used a person-centered treatment (PeT) effects model to assess 
heterogeneity of individual-level treatment effects among diverse subpopulations of PCMH 
enrollees, including the effects of beneficiary race, age, sex, rurality, and number of 
comorbid conditions. 
Data Collection: Medicaid claims merged with provider- and area-level data. 
Principal Findings: We found significant heterogeneity of treatment effects among 
PCMH enrollees, driven by patient race, sex, age, rurality, and number of chronic 
comorbidities. For four of six outcomes, being a racial/ethnic minority was predictive of 
deriving less benefit from the PCMH in terms of quality outcomes. Rural residence is 
predictive of increased benefit from the PCMH in terms of mental health services. an 
increase in number of comorbid chronic conditions was predictive of a small decrease in 
benefit in terms of all quality measures except use of antidepressants. 
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Conclusions: Our findings suggest that the PCMH alone may be insufficient to meet 
the needs of diverse patient populations. Providers and policymakers should consider 
heterogeneous treatment effects explicitly when designing, implementing, and evaluating 
PCMH programs. 
Background/Significance 
Persons with multiple chronic conditions utilize health care services more frequently and 
access a wider range of services than the general population, making coordination of their 
care more difficult.1,2 Because mental health problems exacerbate the consequences of 
physical chronic conditions and complicate their management,3 coordination challenges 
make persons with co-occurring mental illnesses such as depression particularly vulnerable 
to suboptimal quality of care.1,4 Racial minorities with depression and other chronic 
conditions may be particularly susceptible to poor quality of care,5 especially given that a 
higher proportion of individuals in minority communities have unmet mental and physical 
health needs.6,7 Because racial minorities are more likely to seek mental health treatment 
from a primary provider than a mental health specialist, it is important to understand the 
potential for primary care models to address the intersection between race, depression, and 
chronic disease.5,7 
The patient-centered medical home (PCMH) is an increasingly popular model to 
improve the quality of primary care, and several provisions of the Affordable Care Act 
incentivize the use of accredited PCMH models for patients with comorbid mental and 
physical health conditions.8 The primary goal of the PCMH is to provide patient-centered, 
comprehensive, coordinated, and accessible care.9 While the evidence that the PCMH 
improves overall quality of care is growing,9,10 previous research has found that different 
racial groups may not benefit equally from the PCMH.11–13 Some studies have found that the 
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PCMH model reduces or eliminates racial disparities in quality of care metrics such as 
preventive care reminders, cholesterol testing, and cancer screenings,14 others report varying 
effects among racial/ethnic groups.15–18 
However, even within racial groups, not all patients will receive the same benefit 
from PCMH; a phenomenon, known as heterogeneity of treatment effects (HTE).  HTE is 
driven by several factors, including disease severity, responsiveness to treatment, 
susceptibility to adverse treatment effects, decision-making processes and patients’ utility for 
different outcomes.19,20 Estimating the average effects of PCMH enrollment can be useful to 
understand its overall impact; however, in the presence of HTE, the average marginal effect 
may obscure more nuanced patterns of treatment response where some patients benefit 
substantially while others experience no benefit or even detrimental effects.19 Moreover, 
patients and providers may be aware of factors that moderate HTE, which leads to selection 
bias based on the expected benefits from treatment; this is known as essential 
heterogeneity.21 
Understanding individual variation in outcomes can guide policymakers in targeting 
PCMH outreach to specific groups requiring enhanced or additional care. In this study, we 
use a novel method to account for differential selection into the PCMH and assess 
heterogeneity in the response to PCMH enrollment. Using local instrumental variable (LIV) 
methods, we estimate patient-centered treatment effects (PeT) to explore treatment effect 
heterogeneity across both observable patient characteristics and unobserved confounders.22,23 
This innovative approach assesses patient-level heterogeneity by taking individual treatment 
choices into account when predicting personalized treatment effects in observational data.22 
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We then used these individualized estimates to predict the characteristics of beneficiaries 
who are most likely to benefit from the PCMH model. 
Methods 
Data 
We constructed a dataset using several administrative sources. We merged 2008-2011 
Medicaid Analytic eXtract (MAX) claims data which contain enrollment information and 
final claims for all enrolled Medicaid beneficiaries with data from the National Plan and 
Provider Enumeration System (NPPES). The NPPES contains National Provider Identifiers 
(NPIs) from practicing providers and organizations, along with provider characteristics 
including gender, provider type, state, and Medicaid billing identifiers. These data were also 
combined with NCQA PCMH data, which includes the date, duration, and level of NCQA 
PCMH recognition. We obtained county supply of mental health professionals from the Area 
Health Resource File,24 and socioeconomic variables were measured at the county level using 
the U.S. Census Bureau’s Small Area Income and Poverty Estimates.25 
The study population includes Medicaid beneficiaries in three states (GA, NC, TX), 
ages 18-64 with a major depressive disorder (MDD) and at least one comorbid physical 
chronic condition. We focused on this population because quality outcomes are known to be 
poor for this group and because Medicaid beneficiaries have disproportionately high rates of 
comorbid psychiatric conditions4,26,27 To avoid “rule-out” diagnoses and/or errors in coding, 
we defined depression and diabetes cohorts as those beneficiaries having at least one 
inpatient diagnosis or at least two outpatient or emergency department diagnoses during a 
single year in the study period, as well as at least one claim for the condition in the each year. 
We excluded individuals who were dually enrolled in Medicaid and Medicare because their 
Medicaid claims may not be complete. Additionally, we excluded individuals with 
 83 
schizophrenia or bipolar disorder because this population is more likely to see a specialty 
provider as their primary point of contact with the healthcare system.31 
The primary analyses were conducted at the person-year level, controlling for number 
of months of Medicaid enrollment in each year. However, due to the episodic nature of MDD 
we also constructed episode-level variables for antidepressant use. We focused on the acute 
phase of MDD treatment because there are clear guidelines for antidepressant usage during 
this phase.32 We defined the beginning of an acute episode as two MDD outpatient services 
on different dates or initiation of an antidepressant prescription; the end of an episode was 
defined as either 90 days of no antidepressants or 120 days after the start of the episode.33 We 
were unable to observe prescriptions dispensed during inpatient hospitalizations, therefore, 
we adjusted for inpatient episodes by assuming that patients received dispensed medication 
during their hospitalization and continued outpatient antidepressants after discharge. 
Key Measures 
We assessed seven disease-specific quality indicators for MDD and diabetes derived 
from Medicaid claims (see Table 15 for full definitions). We conducted subgroup analyses 
for beneficiaries with comorbid diabetes (Type I and Type II) because it is highly prevalent 
in Medicaid populations28,29 and evidence indicates that comorbid MDD interferes with its 
management.30  We selected annual quality measures based on recommended core measures 
for the PCMH,34 the Centers for Medicare and Medicaid Services (CMS) 2016 core set of 
adult quality measures for Medicaid,35 and the 2011 version of the Healthcare Effectiveness 
Data and Information Set (HEDIS). Clinical guidelines from the American Psychiatric 
Association specify that use of antidepressants or psychotherapy should be based on 
individual clinical circumstances such as disease severity and “complex psychosocial 
situations.”36 This information is not available in claims data, therefore we measured the 
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likelihood that beneficiaries with MDD received any psychotherapy or any antidepressant 
prescriptions. Either treatment modality would be considered guideline-concordant, but these 
measures represent a minimum standard of quality.33,37 In episodic analyses, we assessed the 
HEDIS antidepressant management measure for acute phase treatment, which is defined as 
the receiving at least 84 days of antidepressants during an acute episode.32 
The treatment variable was a binary indicator of yearly engagement in an NCQA-
certified PCMH. We identified primary care providers using NPPES taxonomy codes, and 
NCQA-recognized PCMH providers were identified using NCQA recognition data. We 
attributed patients to a primary care practice using the “plurality rule” commonly applied by 
CMS38 in which we defined a beneficiary’s attributed primary care provider as the provider 
that delivered the plurality of the beneficiary’s non-hospital evaluation and management 
(NH-E&M) visits.39 If a beneficiary received the same number of services from two 
providers, they were attributed to the provider with the most recent claim.39 We also 
modified this method by attributing beneficiaries first to the practice where they received the 
plurality of depression-related NH E&M claims. If a beneficiary had no depression-related 
NH E&M claims, they were attributed to the provider where they received the plurality of 
general NH E&M services. 
Beneficiary variables included age, sex, number of chronic comorbidities, number of 
Medicaid-enrolled months and rurality. Chronic conditions were identified by International 
Classification of Disease (ICD9-CM) diagnosis codes using the Agency for Healthcare 
Research and Quality’s Chronic Condition Indicator software.40 Under this method, a chronic 
comorbidity was defined as a condition lasting at least 12 months and limiting self-care, 
independent living, and social interactions or resulting in need for ongoing medical 
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intervention.40 Rurality was measured as urban, rural, or mixed using simplified county-level 
Rural-Urban Continuum Codes.41 Provider-level covariates included Federally Qualified 
Health Center or Rural Health Center status and sex. County-level socioeconomic variables 
included percent of the population under poverty and median income. Finally, we controlled 
for county-level saturation of mental health professionals using county supply of 
psychiatrists and Mental Health Professional Shortage Area (HPSA) status (full or partial) 
using data from the Area Health Resource File.24 
We created two continuous instrumental variables based on county rates of PCMH 
adoption: (1) the overall ratio of county PCMH adoption, defined as the number of unique 
PCMH providers in a county divided by the total number of primary care providers as 
measured by NCQA PCMH recognition data and the Area Health Resource File and (2) a 
similar county-level rate of NCQA medical home practices to all primary care providers, but 
both the numerator and denominator were contingent on the provider NPI appearing in 
Medicaid MAX claims during the study period. 
Statistical Analyses 
This analysis uses a PeT approach to understand heterogeneity of individual-level 
treatment effects among diverse subpopulations of PCMH enrollees. Using LIV techniques, 
PeT models can explore HTE across both observable characteristics and unobserved 
confounders by estimating marginal treatment effects (MTEs) parameters. MTEs are an 
average treatment effect that would be expected for patients who would be indifferent 
between receiving and not receiving treatment under random assignment.42,43 The PeT 
methodology estimates an individualized treatment effect by averaging over MTEs that 
correspond to an individual’s observed characteristics and the unobserved confounders 
associated with their observed treatment selection.22,44 
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We estimated individual-level PeT effects of PCMH enrollment for seven  disease-
specific quality outcomes. To estimate the PeT effects, we first used a logit model to estimate 
the propensity of PCMH enrollment as a function of baseline characteristics and two 
instrumental variables (Equation 1). 
Equation 1: PCMH_enrollmentit = β0 + β1*instrumentsct + β2*Xipct+ εipct 
where X represents a vector of covariates and i, p, and c represent individual, provider, and 
county level variables and t is the time-period (year). This is analogous to the first stage in 
instrumental variable methods such as two stage residual inclusion. Next, we determined the 
appropriate specification for the second stage or outcome models. We used Wald tests to 
assess whether higher order or interaction terms improved model fit for the second stage 
model. We examined age as a quadratic variable and interactions between race and medical 
home status, median income, percent under poverty, and gender. Only the quadratic form of 
age improved model fit. Finally, we included state and year fixed effects as controls in the 
outcome models. 
We then used the LIV techniques described above to estimate individual PeT effects 
for each quality outcome. Using 1,000 bootstrap replicates, we created a distribution of PeT 
effects for each individual, averaging over the PeT effects if the same individual was 
sampled multiple times within the same replicate.45 Using these distributions, we determined 
which beneficiaries had PeT effects that were statistically significant at the 5% level. Finally, 
we examined which patient characteristics were predictive of increased benefit from the 
PCMH intervention using only statistically significant PeT effects as outcomes and 
regressing them on patient characteristics including race/ethnicity, age, sex, number of 
comorbidities, and rurality. All analyses were performed using Stata (Version 13). 
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Results 
Our instruments were uniformly strong, with F statistics ranging from 987.97 to 
4128.06. The final sample consisted of 261,602 person-years contributed by 181,139 
individuals; 4,376 person-years (1.67% of the sample) were attributed to a PCMH, leaving 
257,226 person-years as controls. PCMH enrollees were more likely to be Black (38.3% vs 
28.5%), less likely to be Hispanic/Latino (3.8% vs 12.5%), and less likely to live in rural 
areas (Table 16). LIV methods only identify parameters over the range of support provided 
by the first-stage propensity score; in this sample propensity scores for PCMH engagement 
ranged from 8.86e^-07 to 0.87. We found that 95.49% of the sample (249,816 person-years) 
had statistically significant PeT effects for at least one of the depression outcomes. We 
excluded the remaining 11,786 person-years with PeT effects did not reach statistical 
significance for either psychotherapy or antidepressant use. 
The diabetes subsample consisted of 82,669 person-years contributed by 38,149 
unique individuals. Medical home enrollees contributed 1,036 person-years and comprised 
1.62% of the diabetes subsample. Propensity scores for PCMH engagement ranged from 
1.22e^-06 to 0.772 in the diabetes sample. 22.48% of person-years had PeT effects that did 
not reach statistical significance; therefore, the final diabetes subsample consisted of 58,477 
person-years that had a statistically significant PeT effect for at least one of the four diabetes-
specific outcomes. 
Table 17 shows the characteristics associated with increased benefit from the PCMH, 
positive coefficients indicate characteristics that make beneficiaries significantly more likely 
to benefit from PCMH enrollment (where “benefit” is defined as a differential increase in the 
likelihood of receiving recommended services). We found that Black race was predictive of 
increased benefit of 12.40 percentage points in terms of receipt of psychotherapy and 3.00 
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percentage points in terms of lipids testing but associated with a reduced likelihood of 
antidepressant use (-33.1 percentage points), A1c testing (-3.10 percentage points), receipt of 
eye exams (-.239 percentage points), and attention for nephropathy (-1.71 percentage points). 
Hispanic/Latino ethnicity was predictive of a differential increase of 36.7 percentage points 
in terms of receipt of psychotherapy but associated with reduced benefit in terms of 
antidepressant use and all four diabetes-specific outcomes. 
Being female was predictive of increased benefit from PCMH enrollment in terms of 
lipids testing (4.16 percentage points), A1c testing (3.98 percentage points), and eye exams 
(1.25 percentage points), and reduced benefit in terms of psychotherapy (-0.69 percentage 
points), antidepressant use (-1.28 percentage points), and attention for nephropathy (-2.06 
percentage points). Overall, beneficiaries residing in rural areas were predicted to have less 
benefit for all diabetes services, except for an increased benefit in terms of eye exams for 
beneficiaries residing in rural counties that are not adjacent to a metropolitan area. However, 
rural residents were predicted to receive increased benefit for depression services. Older 
beneficiaries were likely to see small increases benefit from the PCMH in terms of 
psychotherapy, antidepressant use, and lipids and A1c testing, but decreased benefits for 
receipt of eye exams and attention for nephropathy. Notably, we found that an increase in 
number of comorbid chronic conditions was predictive of a small decrease in benefit in terms 
of all quality measures except use of antidepressants. 
Discussion 
These results suggest that considerable HTE exists among PCMH enrollees, and this 
heterogeneity is driven by patient race, sex, age, rurality, and number of chronic 
comorbidities.  For five of seven outcomes, being a racial/ethnic minority was predictive of 
deriving less benefit from the PCMH in terms of quality outcomes. These findings suggest 
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that the PCMH model is not adequately addressing the factors driving disparities in quality of 
care for racial minorities. We found that Black race and Hispanic/Latino ethnicity were 
predictive of increased benefit of the PCMH for psychotherapy, but decreased benefit for 
antidepressants. This finding may be due to differing patient preferences across racial groups; 
studies have shown that African-Americans and Latinos have differing beliefs and treatment 
preferences regarding depression than their white counterparts.46 For example, African 
Americans and Latinos are both less likely than white patients to find antidepressant 
medication acceptable, and Latinos are more likely to find counseling acceptable.47 
Interestingly, we found that an increase in the number of comorbid chronic diagnoses 
is associated with a slight decrease in quality of care that a beneficiary is expected to derive 
from PCMH enrollment (apart from antidepressant use). This finding is notable because the 
PCMH model has typically focused on the management of chronic conditions and is 
frequently touted as a solution for improving care for individuals with multiple chronic 
conditions.48 
Being female was predictive of increased benefit from the PCMH in terms of lipids 
panels, A1c testing, and retinal exams, but decreased benefit for receiving psychotherapy, 
antidepressants, or attention for nephropathy. An increase in age was associated with 
increased benefit for four of the seven measures, apart from retinal exams and attention for 
nephropathy. Finally, rural residence is predictive of increased benefit from the PCMH in 
terms of mental health services, which suggests that PCMH enrollment is especially 
advantageous for beneficiaries that live in rural areas. 
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Limitations 
This study has several limitations.  First, these NCQA PCMH recognition is not 
necessarily indicative of the services that a practice provides. Non-PCMH primary care 
practices engage in many of the same activities as NCQA-recognized PCMHs but may not 
seek recognition due to financial or other concerns. Services may also vary between 
recognized PCMHs, as the required recognition criteria are flexible. Second, our findings 
may not generalize beyond Medicaid beneficiaries and NCQA-recognized PCMHs. 
Additionally, some research suggests that specific chronic condition dyads may differentially 
affect patient outcomes,49and our findings do not account for specific combinations of 
disease or include a measure of disease severity. Finally, administrative data we used lack 
information on patient preferences, which could be a significant factor related to HTE. 
Conclusions 
While the PCMH has the potential to improve overall quality of care, our findings 
suggest that the PCMH alone may be insufficient to meet the needs of diverse patient 
populations. Providers and policymakers should consider heterogeneous treatment effects 
explicitly when designing, implementing, and evaluating PCMH programs. 
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Table 15: Disease-Specific Dependent Variables 
Variable Definition 
Calendar-
Year 
Acute 
Episode 
MDD 
Antidepressant 
use 
Percent of patients with MDD who received any 
antidepressant prescriptions. 
X  
At least 84 days of antidepressants during a 120-day 
episode. 
 X 
Psychotherapy 
Percent of patients with MDD receiving any 
group/individual psychotherapy  
X  
Any MDD 
treatment 
Receipt of any antidepressant prescriptions or 
group/individual psychotherapy  
X  
Diabetes 
A1C Testing Percent of diabetic patients receiving A1C testing  X  
LDL-C 
Testing 
Percent of diabetic patients receiving an LDL–C test  X  
Retinal exam Percent of diabetic patients receiving a retinal exam  X  
Nephropathy 
screening 
Percent of diabetic patients screened for nephropathy  X  
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Table 16: Summary Statistics 
 N (%) or Mean (SD) 
 
Non-PCMH PCMH 
p-value  
(t-test or χ2) 
N (person-years) 257,226 4,376 -- 
Race    
     White 133,159 (51.8%) 2,294 (52.4%) <0.001 
     Black 73,490 (28.6%) 1,674 (38.3%)  
     Hispanic/Latino 32,139 (12.5%) 166 (3.8%)  
Female 204,279 (79.4%) 3,537 (80.8%) 0.022 
Rurality    
     Metro-adjacent 56,236 (21.9%) 337 (7.7%) <0.001 
     Rural  14,315 (5.6%) 65 (1.5%)  
Age 40.0(13.5) 39.6 (13.3) 0.036 
# Chronic Comorbidities  4.9 (4.2) 5.1 (4.2) 0.002 
 
  
9
3
 
 Table 17: Characteristics Predicting Benefit from PCMH Enrollment 
 
 
 Psychotherapy 
Any 
Antidepressant 
Use 
Minimally 
Adequate 
Antidepressants 
LDL-C 
testing A1c Testing 
Retinal 
Exams 
Attention for 
Nephropathy 
Race              
     Black 0.124*** -0.331*** -0.274*** 0.0300*** -0.0310*** -0.0239*** -0.0171*** 
 (0.00122) (0.00145) (0.00124) (0.00234) (0.00325) (0.000928) (0.00471) 
     Hispanic/Latino 0.367*** -0.351*** -0.256*** -0.0942*** -0.0208** -0.106*** -0.0205*** 
 (0.00264) (0.00139) (0.00118) (0.00404) (0.00983) (0.00129) (0.00653) 
Female  -0.00694*** -0.0128*** -0.0383*** 0.0416*** 0.0398*** 0.0125*** -0.0206*** 
 (0.00142) (0.00137) (0.00118) (0.00252) (0.00243) (0.000966) (0.00533) 
Rurality        
     Metro-adjacent 0.308*** 0.218*** 0.136*** -0.0743*** -0.122*** -0.0315*** -0.174*** 
 (0.00200) (0.00161) (0.00158) (0.00253) (0.00265) (0.00208) (0.00616) 
     Rural  0.696*** 0.349*** 0.304*** -0.0808*** -0.126*** 0.0243*** -0.141*** 
 (0.00315) (0.00252) (0.00301) (0.00709) (0.00444) (0.00659) (0.00948) 
# Chronic Comorbidities -0.00197*** 0.000995*** -0.000673*** -0.00319*** -0.00451*** -8.88e-05 -0.00175*** 
 (0.000156) (0.000143) (0.000136) (0.000247) (0.000294) (9.07e-05) (0.000495) 
Age 0.00362*** 0.00811*** 0.00175*** 0.000843*** 0.000437*** -0.00132*** -0.0191*** 
 (4.72e-05) (4.56e-05) (3.81e-05) (9.70e-05) (0.000139) (6.13e-05) (0.000161) 
 
  
 
    
N (person-years) 199,955 194,777 87,604 38,234 13,920 43,541 15,050 
Robust standard errors in parentheses 
*** p<0.01 
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CHAPTER 5: DISCUSSION 
Overview of Findings 
These studies produced several notable findings that contribute to the literature on the 
effect of the PCMH model on quality of care and racial/ethnic disparities. We found that 
while PCMH enrollment generally improves quality of care metrics for Medicaid 
beneficiaries with depression and other chronic conditions, this effect is not necessarily 
consistent across racial groups. Although many providers and policymakers believe that the 
PCMH model should reduce racial disparities by addressing barriers to high-quality care that 
disproportionately affect racial minorities,1 our findings do not support this view. Overall the 
effect of the PCMH model on racial/ethnic disparities was inconsistent; PCMH enrollment 
was associated with a reduction in racial/ethnic disparities in quality of care for some quality 
metrics, but in other cases disparities were unchanged or even exacerbated. Therefore, 
implementing a PCMH model alone may not be sufficient to address racial inequities in 
health care. These findings run counter to our initial hypothesis that PCMH enrollment would 
reduce disparities in quality of care. 
We also found that higher levels of NCQA PCMH recognition are not directly 
associated with improved quality outcomes. This finding may be because providers seeking 
NCQA recognition can choose from a flexible set of criteria, meaning that services offered 
may be heterogeneous even among providers with the same level of recognition. 
Additionally, because we compared providers before and after receiving NCQA recognition, 
another explanation for these findings is that providers that seek NCQA recognition may 
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already be providing higher quality of care. However, we did find that enrollment in a higher 
level of NCQA-recognized PCMH is sometimes associated with a reduction in racial/ethnic 
disparities in quality. This suggests that incentivizing practices to attain higher levels of 
NCQA recognition has the potential to reduce disparities, but higher levels of NCQA 
recognition alone may not be sufficient. These findings also contradict our original 
hypothesis that higher levels of PCMH enrollment would be associated with reduced 
racial/ethnic disparities in care.  This may be due to the fact that providers choose from a 
flexible set of recognition criteria, meaning that PCMH providers with the same level of 
recognition may offer differing services. 
Notably, we found that Black race and Hispanic/Latino ethnicity were predictive of 
increased benefit of the PCMH for psychotherapy, but decreased benefit for antidepressants. 
This may be indicative of increased attention to patient preference by PCMH providers; 
studies have shown that Black and Hispanic/Latino patients have different beliefs and 
preferences about depression treatment than their white counterparts.46 For example, Black 
and Hispanic/Latino patients are both less likely than white patients to find antidepressant 
medication acceptable, and Hispanic/Latino patients are more likely to find counseling 
acceptable.47 Therefore, the fact that Black and Hispanic/Latino beneficiaries enrolled in a 
PCMH are less likely to receive antidepressants may reflect the fact that PCMH providers are 
more likely consider patient preference when making treatment decisions. However, our 
analyses are based on administrative data that do not contain information on patient 
preference; future research should assess the role that patient preference plays in racial 
disparities in depression treatment in the PCMH. 
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Finally, we found considerable heterogeneity of treatment effects among PCMH 
enrollees; racial minorities were predicted to derive less benefit from PCMH enrollment than 
their white counterparts. We also found that other patient characteristics including sex, 
rurality, number of chronic comorbidities, and age also affected the likelihood of benefitting 
from PCMH services. These results suggest that while the PCMH has the potential to 
improve overall quality of care, this model alone may not be sufficient to meet the needs of 
diverse patient populations. 
Policy Implications 
Our findings suggest that while the PCMH model is associated with an improvement 
in quality metrics on average, estimating the average effects of PCMH enrollment obscures 
more nuanced patterns of treatment response. These findings highlight the importance of 
documenting and analyzing racial/ethnic disparities among PCMH enrollees. Providers, 
administrators, and policymakers should plan to explicitly address racial/ethnic disparities 
when designing, implementing, and evaluating PCMH programs. This may include designing 
culturally competent PCMH interventions, collecting and analyzing race-specific data, and 
incorporating efforts to address social determinants of health. 
Additionally, we found that recognition as an NCQA PCMH improved quality 
metrics, but that there was no direct association between level of recognition and quality 
outcomes. This suggests that state Medicaid programs should incentivize NCQA-recognition, 
but that offering additional incentives based on level of recognition may not lead to improved 
process quality outcomes. 
Areas for Future Research 
Our studies use data on NCQA-recognized PCMH providers from 2008-2011. This 
study period reflects the early stages of the NCQA recognition program, and the PCMH 
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recognition standards have since been updated. Many of the disparities-related concerns 
raised by our findings are reflected in the NCQA’s latest PCMH recognition standards, 
released in 2017. These new standards have several criteria relating to equity of care, 
including “targeting population health management on disparities in care,” and “using 
information on the population served by the practice to assess equity of access.”2 Future 
research should assess whether these new standards are more effective at reducing racial 
disparities in quality of care. 
Our findings also show that the PCMH has the potential to reduce racial disparities in 
quality. However, the PCMH is a multifaceted intervention and it is not clear which elements 
of this model are most effective at improving equity of care and why. Future research should 
assess which PCMH components (e.g. care coordination, enhanced access, etc.) is most 
important for improving care for racial/ethnic minorities and reducing disparities. Moreover, 
some research shows that the heterogeneous implementation of the PCMH model may 
exacerbate disparities if PCMH services are implemented unequally across providers serving 
minority and non-minority communities.3 Therefore, future studies should explore the effect 
of implementation fidelity on quality and equity of care. 
Finally, our studies rely on administrative claims data, which does not contain 
information on patient preference or experience of care. This is particularly important for 
disparities research because patient preference is a crucial aspect of the IOM definition of 
health care disparities. Future data collection and research should focus on assessing patient 
preferences and satisfaction with care in the PCMH model, especially in diverse populations. 
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